CN109721579A - The plain derivative of 7,8- dehydrogenation grapevine penta, its preparation method and pharmaceutical composition and purposes - Google Patents
The plain derivative of 7,8- dehydrogenation grapevine penta, its preparation method and pharmaceutical composition and purposes Download PDFInfo
- Publication number
- CN109721579A CN109721579A CN201811265797.2A CN201811265797A CN109721579A CN 109721579 A CN109721579 A CN 109721579A CN 201811265797 A CN201811265797 A CN 201811265797A CN 109721579 A CN109721579 A CN 109721579A
- Authority
- CN
- China
- Prior art keywords
- unsubstituted
- substituted
- group
- hydroxyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses plain (Amurensin H) derivative of a kind of novel 7,8- dehydrogenation grapevine penta with anti-inflammatory activity and its anti-inflammatory activities.Replace benzofuran derivatives or its medically acceptable salt specifically related to a kind of new structural 2,3- diaryl -4- as shown in logical formula (I).The invention discloses the application of this kind of derivatives monomer or Pharmaceutical composition in the clinical treatment of inflammatory related disease.
Description
Technical field
The present invention relates to biomedicine fields, and in particular to one kind has 7, the 8- dehydrogenation grapevine penta of benzofuran structure
Plain (Amurensin H) derivative or its medically acceptable salt, the Pharmaceutical composition containing these derivatives and its in inflammation
Application in the clinical treatment of disease property related disease.
Background technique
Inflammation is the illness basis of human diseases, and numerous lesion reciprocal causations with disease are the pass of disease pathology process
Key link.However, current anti-inflammatory drug, such as corticoid and non-steroid anti-inflammatory drug, there are still more in clinical application
Problem such as easily causes alimentary canal discomfort, bleeding, increases the adverse reactions wind such as heart disease or the generation of whole body blood coagulation disorders disease
Danger.Therefore, the vital task that safer effective anti-inflammatory drug is still current anti-inflammatory drug research and development is found.
Oligomerization stilbene compound is the new structural natural products of one kind to grow up for nearly 30 years, studies have shown that such
Compound has a variety of pharmacological activity, the including [J.Asian such as antibacterial, anti-inflammatory, anti-oxidant, antiviral, anti-senile dementia
Nat.Prod.Res., 2016,18 (4): 376-407], there is preferable research and development prospect.Currently, to such compound
It extracts separation, Structural Identification and Preliminary activation screening and numerous studies has been carried out.However, naturally being produced since structure is complicated
Universal content is less in object, fully synthetic often relatively difficult, and the exploitation that the shortage of sample size greatly limits such compound is ground
Study carefully process.Therefore, based on activated oligomeric Stilbene class lead compound, pass through synthesis, structure optimization and structure activity study, hair
Now new, the better drug of druggability is of great significance to such compound is developed and used.
Amurensin H is one isolated from folk medicinal plants V. amurensis (Vitis amurensis) root
Resveratrol dimer compound [Chin.Chem.Lett., 1999,10 (10): 817-820] with benzofuran structure.
Pharmacology activity research discovery, Amurensin H be one to the generation of a variety of inflammatory mediators have the natural activity of inhibiting effect at
Divide [Acta.Pharmacol.Sin., 2006,27 (6): 735-740.], animal model test confirms that the compound can be supported significantly
Chronic obstructive pulmonary disease (COPD) mouse lung tissue pathology damage is suffered from anti-chronic airway inflammation, alleviation.The pharmacology of further system
Experiment display, natural products activity is strong, and toxicity is smaller, is an active lead compound with further investigation value.
This study group of research of Amurensin H compound activity aspect itself has disclosed report, but the related system of compounds
Structure optimization and anti-inflammatory activity in terms of structure activity study have no document report mistake so far.This patent is related to this compound
Structure optimization and structure activity study are carried out to improve the work of its physicochemical property and interior anti-inflammatory activity
Summary of the invention
The technical problem to be solved by the present invention is to 3, the 4- diphenyl -4- for providing a kind of new construction replaces benzofurans
Compound and its derivative, preparation method, pharmaceutical composition and purposes.
The first aspect of technical solution of the present invention provide it is a kind of as logical formula (I), (IA), (IAa), (IAb), (IAc),
(IAd) and (IB), (IBa), (IBb), (IBc), new construction 2,3- diphenyl -4- shown in (IBd) replace benzofurans
Close object and its derivative.
The second aspect of technical solution of the present invention provides a kind of pharmaceutical composition, including at least one such as general formula
(I), (IA), (IAa), (IAb), (IAc), (IAd) and (IB), (IBa), (IBb), (IBc), 2,3- hexichol shown in (IBd)
Base -4- replaces common carrier in benzofuran compounds and its pharmaceutically acceptable salt and pharmaceutical field.
The third aspect of technical solution of the present invention provides such as general formula ((I), (IA), (IAa), (IAb), (IAc), (IAd)
And (IB), (IBa), (IBb), (IBc), 2,3- diphenyl -4- shown in (IBd) replace benzofuran compounds and its pharmacy
Upper acceptable salt is preparing the application in the drug for preventing, treating and assisting in the treatment of various inflammatory diseases.
The fourth aspect of technical solution of the present invention is to provide the preparation method of derivative described in first aspect.
The various inflammatory diseases include: rheumatoid arthritis, osteoarthritis, rheumatic arthritis, gouty pass
Save inflammation, lupus erythematosus syndrome, bronchitis, bursal synovitis, tenosynovitis, psoriasis, eczema, burn, dermatitis, inflammatory bowel disease, gram
Labor grace disease, gastritis, irritable bowel syndrome, ulcerative colitis, multiple sclerosis, Autoimmune Encephalomyelitis, colon
The carcinoma of the rectum, arteritis nodosa, thyroiditis, wind-heat be wet, gingivitis, periodontitis, canker sore, ephritis, occurs after damage
Swelling, myocardial ischemia, various infectious pneumonias, physics and chemistry pneumonia and allergy pneumonia, Chronic Obstructive Pulmonary Disease, heavy breathing
Asthma, proctalgia fugax and rectum split, liver and gallbladder capsulitis, cholangitis, sclerosing cholangitis, primary biliary cirrhosis and gall-bladder
It is scorching.Compound of the present invention includes acceptable salt in its derivative and pharmacodynamics.
Specifically, the present invention relates to such as plain derivative (2, the 3- hexichol of 7,8- dehydrogenation grapevine penta shown in logical formula (I)
Base -4- replaces benzofuran derivatives) and its pharmaceutically acceptable salt:
Wherein, X is selected from O, NR6,S;
R1Selected from H, substituted or unsubstituted C3-8Naphthenic base, substituted or unsubstituted phenyl, substituted or unsubstituted Yin
Diindyl base, substituted or unsubstituted furyl, substituted or unsubstituted naphthalene, substituted or unsubstituted quinolyl, substitution do not take
The pyridyl group in generation;Wherein the substituent group of the naphthenic base, phenyl, indyl, furyl, naphthalene, quinolyl and pyridyl group is selected from
Hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyl
Oxygroup, C1-6Alkylthio group, methylene-dioxy, carboxyl, F, Cl, Br, I, Glu, SO3H、PO3H2;Replace type include it is monosubstituted,
Two substitutions or three substitutions;
L1Selected from substituted or unsubstituted C0-16Linear or branched alkyl group, substituted or unsubstituted C0-16Straight chain or branch
Chain acyl, substituted or unsubstituted C2-16Linear chain or branched chain alkenyl, C2-6Alkynyl;The substituent group be selected from hydroxyl, nitro,
Cyano, amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6Alkylthio group,
F,Cl,Br,I;
R6Independently selected from H, substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C1-6Acyl group;Wherein, it takes
Dai Ji is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkoxy, phenyl, F, Cl, Br, I;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、 PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
, according to the invention it is preferred to logical formula (I) shown in the plain derivative of 7,8- dehydrogenation grapevine penta including but not limited to
General formula (IA) compound represented and its pharmaceutically acceptable salt, which is characterized in that the compound is as shown in general formula IA:
Wherein, R1Selected from H, substituted or unsubstituted C3-8Naphthenic base, substituted or unsubstituted phenyl, substitution or do not take
The indyl in generation, substituted or unsubstituted furyl, substituted or unsubstituted naphthalene, substituted or unsubstituted quinolyl, substitution
Or unsubstituted pyridyl group;The wherein substitution of the naphthenic base, phenyl, indyl, furyl, naphthalene, quinolyl and pyridyl group
Base is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkyl, C1-6Alkoxy, C1-6Acyl group, C1-6
Acyloxy, C1-6Alkylthio group, methylene-dioxy, carboxyl, F, Cl, Br, I, Glu, SO3H、PO3H2;Replacing type includes singly taking
Generation, two substitutions or three substitutions;
L1Selected from substituted or unsubstituted C0-16Linear or branched alkyl group, substituted or unsubstituted C0-16Straight chain or branch
Chain acyl, substituted or unsubstituted C2-16Linear chain or branched chain alkenyl, C2-6Alkynyl;The substituent group be selected from hydroxyl, nitro,
Cyano, amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6Alkylthio group,
F,Cl,Br,I;
R6Independently selected from H, substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C1-6Acyl group;Wherein, it takes
Dai Ji is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkoxy, phenyl, F, Cl, Br, I;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、 PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
, according to the invention it is preferred to general formula (IA) shown in the plain derivative of 7,8- dehydrogenation grapevine penta include but not limiting
In general formula (IAa), (IAb), (IAc) compound represented and its pharmaceutically acceptable salt, which is characterized in that the chemical combination
Object such as general formula (IAa), (IAb), (IAc) are shown:
Wherein, L1Selected from substituted or unsubstituted C0-16Linear or branched alkyl group, substituted or unsubstituted C0-16Straight chain
Or branched chain acyl, substituted or unsubstituted C2-16Linear chain or branched chain alkenyl;The substituent group is selected from hydroxyl, nitro, cyano, ammonia
Base, methylamino, dimethylamino, phenyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, F, Cl, Br, I;
R6Independently selected from H, substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C1-6Acyl group;Wherein, it takes
Dai Ji is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkoxy, phenyl, F, Cl, Br, I;
R7、R8、R9It is each independently selected from hydrogen, hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkane
Base, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6Alkylthio group, methylene-dioxy, F, Cl, Br, I, Glu,
SO3H、PO3H2;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、 PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
, according to the invention it is preferred to general formula (IAa), (IAb), the plain derivative of 7,8- dehydrogenation grapevine penta shown in (IAc),
And its pharmaceutically acceptable salt, it is characterised in that:
The L1Selected from C0、C1、C2、C3Straight chained alkyl;
R6Independently selected from H, C1、C2、C3Straight chained alkyl;
R7、R8、R9It is each independently selected from hydrogen, hydroxyl, methoxyl group, acetyl group, Cl;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl.
, according to the invention it is preferred to general formula (IA) shown in the plain derivative of 7,8- dehydrogenation grapevine penta include but not limiting
In general formula (IAd) compound represented and its pharmaceutically acceptable salt, which is characterized in that the compound such as general formula (IAd)
It is shown:
Wherein, R10Independently selected from hydrogen, substituted or unsubstituted C3-8Naphthenic base, substituted or unsubstituted C1-16It is straight
Chain or branched alkyl, substituted or unsubstituted C1-16Linear chain or branched chain acyl group, substituted or unsubstituted C2-16Linear chain or branched chain
Alkenyl, C2-6Alkynyl;Wherein, the substituent group be selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, phenyl,
C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, F, Cl, Br, I;
R6Independently selected from H, substituted or unsubstituted C1-6Alkyl;Wherein, substituent group be selected from hydroxyl, nitro, cyano,
Amino, methylamino, dimethylamino, C1-6Alkoxy, phenyl, F, Cl, Br, I;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、 PO3H2, preferably hydrogen,
Methyl, acetyl group;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
, according to the invention it is preferred to general formula (IAd) shown in the plain derivative of 7,8- dehydrogenation grapevine penta, and its pharmaceutically may be used
The salt of receiving, it is characterised in that:
The R10Selected from substituted or unsubstituted C1-16Linear or branched alkyl group, substituted or unsubstituted C3-8Ring
Alkyl;Wherein, the substituent group is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy,
C1-6Acyl group, C1-6Acyloxy, F, Cl, Br, I;
R6Independently selected from hydrogen, C1、C2、C3Straight chained alkyl;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl, acetyl group;
, according to the invention it is preferred to general formula (IAd) shown in the plain derivative of 7,8- dehydrogenation grapevine penta, and its pharmaceutically may be used
The salt of receiving, it is characterised in that:
The R10Selected from substituted or unsubstituted C3-12Linear or branched alkyl group, substituted or unsubstituted C5-6Ring
Alkyl;Wherein, the substituent group is selected from hydrogen, hydroxyl, methylamino, dimethylamino, methoxyl group, acetyl group, Cl;
R6Independently selected from hydrogen, C1、C2、C3Straight chained alkyl;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl, acetyl group;
, according to the invention it is preferred to logical formula (I) shown in the plain derivative of 7,8- dehydrogenation grapevine penta including but not limited to
General formula (IB) compound represented and its pharmaceutically acceptable salt, which is characterized in that the compound such as general formula (IB) institute
Show:
Wherein, R1Selected from H, substituted or unsubstituted C3-8Naphthenic base, substituted or unsubstituted phenyl, substitution or do not take
The indyl in generation, substituted or unsubstituted furyl, substituted or unsubstituted naphthalene, substituted or unsubstituted quinolyl, substitution
Or unsubstituted pyridyl group;The substituent group choosing of the naphthenic base, phenyl, indyl, furyl, naphthalene, quinolyl and pyridyl group
From hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyl
Oxygroup, C1-6Alkylthio group, methylene-dioxy, carboxyl, F, Cl, Br, I, Glu, SO3H、PO3H2;Replace type include it is monosubstituted,
Two substitutions or three substitutions;
L1Selected from substituted or unsubstituted C0-16Linear or branched alkyl group, substituted or unsubstituted C0-16Straight chain or branch
Chain acyl, substituted or unsubstituted C2-16Linear chain or branched chain alkenyl, C2-6Alkynyl;The substituent group be selected from hydroxyl, nitro,
Cyano, amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6Alkylthio group,
F,Cl,Br,I;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、 PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
, according to the invention it is preferred to general formula (IB) shown in the plain derivative of 7,8- dehydrogenation grapevine penta include but not limiting
In general formula (IBa), (IBb), (IBc) compound represented and its pharmaceutically acceptable salt, which is characterized in that the chemical combination
Object such as general formula (IBa), (IBb), (IBc) are shown:
Wherein, L1Selected from substituted or unsubstituted C0-16Linear or branched alkyl group, substituted or unsubstituted C0-16Straight chain
Or branched chain acyl, substituted or unsubstituted C2-16Linear chain or branched chain alkenyl;The substituent group is selected from hydroxyl, nitro, cyano, ammonia
Base, methylamino, dimethylamino, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, F, Cl, Br, I;
R11、R12、R13It is each independently selected from hydrogen, hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkane
Base, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6Alkylthio group, methylene-dioxy, F, Cl, Br, I, Glu,
SO3H、PO3H2;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、 PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
, according to the invention it is preferred to general formula (IBa), (IBb), the plain derivative of 7,8- dehydrogenation grapevine penta shown in (IBc),
And its pharmaceutically acceptable salt, it is characterised in that:
The L1Selected from C1、C2、C3Straight chained alkyl;
R11、R12、R13It is each independently selected from hydrogen, hydroxyl, methoxyl group, acetyl group, Cl;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl, acetyl group.
, according to the invention it is preferred to general formula (IB) shown in the plain derivative of 7,8- dehydrogenation grapevine penta include but not limiting
In general formula (IBd) compound represented and its pharmaceutically acceptable salt, which is characterized in that the compound such as general formula (IBd)
It is shown:
Wherein, R14Independently selected from hydrogen, substituted or unsubstituted C3-8Naphthenic base, substituted or unsubstituted C1-16It is straight
Chain or branched alkyl, substituted or unsubstituted C1-16Linear chain or branched chain acyl group, substituted or unsubstituted C2-16Linear chain or branched chain
Alkenyl, C2-6Alkynyl;Wherein, the substituent group be selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, phenyl,
C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, F, Cl, Br, I;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、 PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
, according to the invention it is preferred to general formula (IBd) shown in the plain derivative of 7,8- dehydrogenation grapevine penta, and its pharmaceutically may be used
The salt of receiving, it is characterised in that:
The R14Selected from substituted or unsubstituted C1-16Straight chain or straight chained alkyl, substituted or unsubstituted C3-8Ring
Alkyl;Wherein, the substituent group is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy,
C1-6Acyloxy, F, Cl, Br, I;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl, acetyl group;
, according to the invention it is preferred to general formula (IBd) shown in the plain derivative of 7,8- dehydrogenation grapevine penta, and its pharmaceutically may be used
The salt of receiving, it is characterised in that:
The R14Selected from substituted or unsubstituted C1-16Straight chain or straight chained alkyl, substituted or unsubstituted C3-8Ring
Alkyl;The substituent group is selected from hydrogen, hydroxyl, methylamino, dimethylamino, methoxyl group, acetyl group, Cl;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl, acetyl group;
Specifically, lead to formula (I), (IA), (IAa), (IAb), (IAc), (IAd) and (IB), (IBa), (IBb),
(IBc), the plain derivative of 7,8- dehydrogenation grapevine penta shown in (IBd) and its pharmaceutically acceptable salt, which is characterized in that described
Compound be selected from following group (compound numbers correspond to embodiment in compound numbers):
The second aspect of technical solution of the present invention there is provided a kind of containing medicine effective dose as logical formula (I),
(IA), (IAa), (IAb), (IAc), (IAd) and (IB), (IBa), (IBb), (IBc), compound described in (IBd) each situation
With the pharmaceutical composition of pharmaceutically acceptable carrier.
According to the present invention, the compounds of this invention can exist in the form of isomers, and usually described " of the present inventionization
Conjunction object " includes the isomers of the compound.
According to an embodiment of the invention, the compounds of this invention further includes its pharmaceutically acceptable salt, salt
Hydrate or pro-drug.
The invention further relates to containing as the compounds of this invention and customary pharmaceutical excipients of active constituent or the medicine of adjuvant
Compositions.Usual pharmaceutical composition of the present invention contains the compounds of this invention of 0.1~95% weight.This hair in unit dosage form
The bright general content of compound is 0.1~100mg, and preferred unit dosage form contains 4~50mg.
The pharmaceutical composition of the compounds of this invention can be prepared according to method well known in the art.When for this purpose, if
It needs, can be by the compounds of this invention in conjunction with one or more solids or liquid pharmaceutical excipients and/or adjuvant, being made can be used as
The administration form or dosage form appropriate that people's medicine or veterinary drug use.
The compounds of this invention can be administered in a unit containing its pharmaceutical composition, and administration route can be enteron aisle
Or non-bowel, such as oral, muscle, subcutaneous, nasal cavity, mucous membrane of mouth, skin, peritonaeum or rectum.The compounds of this invention contains
The administration route of its pharmaceutical composition can be drug administration by injection.Injection includes intravenous injection, intramuscular injection, subcutaneous injection, intradermal
Injection and acupoint injection therapy etc..
Form of administration can be liquid dosage form, solid dosage forms.As liquid dosage form can be true solution class, colloidal type, particle
Dosage form, emulsion dosage form, mixed suspension form.Other dosage forms such as tablet, dripping pill, aerosol, pill, pulvis, solution, mixes capsule
Suspension, emulsion, granule, suppository, freeze drying powder injection etc..
Ordinary preparation can be made in the compounds of this invention, be also possible to sustained release preparation, controlled release preparation, targeting preparation and various
Particulate delivery system.
Such as in order to which tablet is made in unit dosage forms for administration, various carriers well known in the art can be widely used.About
The example of carrier, such as diluent and absorbent, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, grape
Sugar, urea, calcium carbonate, white bole, microcrystalline cellulose, alumina silicate etc.;Wetting agent and adhesive, as water, glycerol, polyethylene glycol,
Ethyl alcohol, propyl alcohol, starch slurry, dextrin, syrup, honey, glucose solution, mucialga of arabic gummy, gelatine size, sodium carboxymethylcellulose,
Lac, methylcellulose, potassium phosphate, polyvinylpyrrolidone etc.;Disintegrating agent, for example, dry starch, alginate, agar powder,
Laminaran, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene sorbitol aliphatic ester, dodecyl sodium sulfate, methyl
Cellulose, ethyl cellulose etc.;Disintegration inhibitor, such as sucrose, glyceryl tristearate, cocoa butter, hydrogenated oil and fat etc.;It absorbs and promotees
Into agent, such as quaternary ammonium salt, lauryl sodium sulfate etc.;Lubricant, such as talcum powder, silica, cornstarch, stearic acid
Salt, boric acid, atoleine, polyethylene glycol etc..Tablet can also be further made to coating tablet, such as sugar coated tablet, film packet
Garment piece, enteric coated tablets or double-layer tablets and multilayer tablet.
Such as in order to which pill is made in administration unit, carrier well known in the art can be widely used.Example about carrier
Son is, such as diluent and absorbent, as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone,
Glycerin monostearate, kaolin, talcum powder etc.;Adhesive, as Arabic gum, bassora gum, gelatin, ethyl alcohol, honey, liquid sugar,
Rice paste or batter etc.;Disintegrating agent, such as agar powder, dry starch, alginate, dodecyl sodium sulfate, methylcellulose, ethyl
Cellulose etc..
Such as in order to which capsule is made in administration unit, the compounds of this invention is mixed with above-mentioned various carriers, and will be by
This obtained mixture is placed in hard gelatine capsule or soft capsule.Micro-capsule can also be made in effective component the compounds of this invention
Agent is suspended in aqueous medium and forms suspension, also can be fitted into hard capsule or be made injection application.
For example, injection preparation is made in the compounds of this invention, such as solution, suspension solution, emulsion, freeze-dried powder
Agent, this preparation can be aqueous or non-aqueous, can contain acceptable carrier in a kind of and/or a variety of pharmacodynamics, diluent, viscous
Mixture, lubricant, preservative, surfactant or dispersing agent.As diluent can be selected from water, ethyl alcohol, polyethylene glycol, 1,3- the third two
Alcohol, the isooctadecanol of ethoxylation, polyoxygenated isooctadecanol, polyoxyethylene sorbitan ester, fatty acid etc..In addition, in order to make
Standby isotonic injection, can add suitable sodium chloride, glucose or glycerol, further, it is also possible to add into injection preparation
Conventional cosolvent, buffer, pH adjusting agent etc..These auxiliary materials are commonly used in the art.
In addition, if desired, can also be added into pharmaceutical preparation colorant, preservative, fragrance, corrigent, sweetener or
Other materials.
To reach medication purpose, enhance therapeutic effect, drug of the invention or pharmaceutical composition well known can be given with any
The administration of prescription method.
The dosage of the compounds of this invention pharmaceutical composition depends on many factors, such as to be prevented or be treated disease
Property and severity, gender, age, weight, personality and the individual reaction of patient or animal, administration route, administration number of times,
Therapeutic purposes, therefore therapeutic dose of the invention can have large-scale variation.In general, making for part is studied in the present invention
It is well known to those skilled in the art with dosage.It can be according to the present invention contained in preparation last in compound composition
Actual drug quantity is subject to adjustment appropriate, to reach the requirement of its therapeutically effective amount, completes prevention or treatment mesh of the invention
's.The daily Suitable dosage ranges of the compounds of this invention: the dosage of the compound of the present invention is 0.001~100mg/kg body
Weight, preferably 0.1~60mg/kg weight, more preferably 1~30mg/kg weight, most preferably 2~15mg/kg weight.It is adult
The compounds of this invention that patient takes is 10~500mg daily, preferably 10~100mg, can once take or divide 2~3 clothes
With;The dosage of children taking is according to 5~30mg of every kg weight, preferably 10~20mg/kg weight.Above-mentioned dosage can be single dose
Amount form is divided into several, such as two, three or four dosage forms for administration, this is limited to the clinical experience of administration doctor and controls
The dosage regimen for the treatment of means.The compound of the present invention or composition can individually be taken, or with other therapeutic agents or symptomatic drugs
Merge and uses.
Another object of the present invention is to provide a kind of benzofuran type talan dimer derivate or it medically may be used
The salt of receiving, the hydrate of salt or pro-drug are preparing the application in anti-inflammatory and immunosupress and its related disease drug.
The diseases associated with inflammation includes rheumatoid arthritis, osteoarthritis, rheumatic arthritis, urarthritis
Lupus erythematosus syndrome, bronchitis, bursal synovitis, tenosynovitis, psoriasis, eczema, burn, dermatitis, inflammatory bowel disease, Ke Laoen
Disease, gastritis, irritable bowel syndrome, ulcerative colitis, multiple sclerosis, Autoimmune Encephalomyelitis, colorectum
The swelling that occurs after cancer, arteritis nodosa, thyroiditis, rheumatic fever, gingivitis, periodontitis, canker sore, ephritis, damage,
Myocardial ischemia, various infectious pneumonias, physics and chemistry pneumonia and allergy pneumonia, Chronic Obstructive Pulmonary Disease, asthma, convulsion
Contraction proctalgia and rectum split, liver and gallbladder capsulitis, cholangitis, sclerosing cholangitis, primary biliary cirrhosis and cholecystitis etc..
The universals of this kind of disease on a cellular level show themselves in that macrophage overactivity, generate excessive NO.
The present invention has carried out the experiment that compound generates NO to the macrophage that inhibition is stimulated through LPS, from cellular level
Illustrate that the benzofuran derivatives of invention have the activity for inhibiting macrophage to generate excessive NO.Meanwhile passing through research invention
Shadow of the compound to croton oil inducing mouse otitis, the immune response of mouse Delayed onset and carrageenan inducing mouse foot swelling
It rings, discovery benzofuran derivatives still have good anti-inflammatory and immunosuppressive activity in vivo.
The fourth aspect of technical solution of the present invention is to provide the preparation method of derivative described in first aspect
It is used to prepare the raw material of the compounds of this invention, such as 3,5- methyl dihydroxy benzoate, 1- (3,5- dimethoxy benzenes
Base) -2- bromoacetophenone, alcohols, phenols and the aminated compounds of different structure can be by commercially available or according to prior art system
It is standby to obtain.
The basic synthetic method of key reaction raw material compound 1d in the present invention includes the following steps:
Step 1: the preparation of 3- methoxyl group -5- methyl hydroxybenzoate.
3,5- methyl dihydroxy benzoate and iodomethane are in acetone in K2CO3It is reacted under solid catalysis, reaction mixing
Object is filtered, and is concentrated under reduced pressure, and obtained solid obtains target product 3- methoxyl group -5- hydroxy benzenes first through recrystallization or chromatographic separation and purification
Sour methyl esters.
Step 2: 3- methoxyl group -5- methyl hydroxybenzoate is reacted with 1- (3,5- Dimethoxyphenyl) -2- bromoacetophenone
Synthesize 3- (2- (3,5- Dimethoxyphenyl) -2- oxygen ethyl) -5- methoxyl methyl benzoate (1a).
3- methoxyl group -5- methyl hydroxybenzoate and 1- (3,5- Dimethoxyphenyl) -2- bromoacetophenone are in anhydrous propanone
In in K2CO3Heating reflux reaction is carried out under the catalysis of solid, reaction solution is concentrated under reduced pressure, and products therefrom is through recrystallization or chromatography point
Target product 1a from purifying.
Step 3: compound 1a cyclization reaction generates compound 1b:
Step 2 products therefrom 1a in methylene chloride, is reacted, reaction solution is washed to by catalyst of Loprazolam
Neutrality is concentrated to dryness, and obtained solid product obtains target product 1b through recrystallization or chromatographic separation and purification.In this reaction, urge
Agent is Loprazolam (MSA), Bismuth triflate (Bi (OTf)3), trifluoroacetic acid (TFA), ferric trichloride (FeCl3), preferably
Loprazolam and Bismuth triflate;Reaction temperature is 25-60 DEG C, preferably 40 DEG C.
Step 4: compound 1b reacts synthesis compound 1c with para-bromoanisole:
Compound 1b obtained by step 3 is in DMA solution, in KOAc solid, Pd (OAc)2Under solid catalysis and to bromobenzene first
Ether is in 120 DEG C of reaction 18h.Reaction solution is filtered with diatomite, organic phase removed under reduced pressure at 80-90 DEG C portion of ethyl acetate and
DMA, the dilution of remaining mixture ethyl acetate, saturated common salt washing, anhydrous sodium sulfate is dry, evaporated under reduced pressure, residue obtained through weight
Crystallization or chromatographic separation and purification obtain target compound compound 1c.
Step 5: compound 1c hydrolysis synthesizes compound 1d:
Compound 1c obtained by step 4 is dissolved in THF, MeOH and H2In the mixed solution of O (1: 1: 1, v/v/v), with NaOH
For catalyst heating reflux reaction, gained reaction solution removes most of solvent under reduced pressure, and 1mol/L is added dropwise into remaining reaction solution
HCl solution to no white precipitate be precipitated until.Reaction mixture filters, and obtained solid is dried white to distill water washing
The powdered solid chemical compound 1d of color.
The basic synthetic method of compound of the present invention includes following two:
First method includes the following steps:
Step 1: compound 1d and alcohols, phenols and aminated compounds pass through condensation reaction synthesizing methoxy ester or methoxy
Yl amine derivatives.
Compound 1d and alcohols, phenols and aminated compounds are under the catalysis of HOBt and EDCI, in dry methylene chloride
Middle carry out condensation reaction, for reaction solution through being concentrated under reduced pressure, products therefrom obtains methoxy base ester or first through recrystallization or chromatographic separation and purification
Oxygroup amine target product.
Step 2: methoxy base ester or Methoxyamine derivative removing methyl synthesis phenolic hydroxyl group ester or phenolic hydroxyl group amine derivative.
Step 1 products therefrom in dry methylene chloride with BBr3Reaction removing methyl is carried out, reaction solution is with water and satisfies
It is concentrated under reduced pressure after washing away acid with saline solution, products therefrom obtains phenolic hydroxyl group ester or phenolic hydroxyl group amine through recrystallization or chromatographic separation and purification
Target product.Specific reaction temperature is -50 DEG C -25 DEG C.
Second method includes the following steps:
Step 1: compound 1d and alcohols, phenols and aminated compounds carry out condensation reaction synthesizing methoxy ester or methoxy
Yl amine derivatives.
Compound 1d and alcohols, phenols and aminated compounds are under the catalysis of DMAP and EDCI, in dry methylene chloride
Middle carry out condensation reaction, for reaction solution through being concentrated under reduced pressure, products therefrom obtains methoxy base ester or first through recrystallization or chromatographic separation and purification
Oxygroup amine target product.
Step 2: methoxy base ester or Methoxyamine derivative removing methyl synthesis phenolic hydroxyl group ester or phenolic hydroxyl group amine derivative.
The product that step 1 obtains in dry methylene chloride with BBr3Carry out reaction removing methyl, reaction solution with water and
After saturated salt solution washes away acid, products therefrom is concentrated under reduced pressure through recrystallization or chromatographic separation and purification and obtains phenolic hydroxyl group ester or phenolic hydroxyl group amine
Class target product.Specific reaction temperature is -50 DEG C -25 DEG C.
Advantageous effects
Currently, although having had more document report to the anti-inflammatory activity of the compound with benzofuran structure,
Up to the present, not yet to the structure activity study of the system of the talan dimer class compound with benzofuran structure
See document report, had no in existing literature and technology about plain (Amurensin H) derivative of 7,8- dehydrogenation grapevine penta or its
Medically acceptable salt and such compound are used to treat the report of diseases associated with inflammation;It has no and is taken about 2,3- diphenyl -4
For benzofurans novel compound or its medically acceptable salt and such compound for treating diseases associated with inflammation
Report.
Detailed description of the invention:
C3-8Naphthenic base refer to carbon atom number be 3,4,5,6,7,8 substituted or unsubstituted naphthenic base, C2-6Alkynyl
Refer to that carbon atom number is 2,3,4,5,6 linear chain or branched chain alkynyl, C0-3Straight chained alkyl refer to that carbon atom number is 0,1,2,3
Straight chained alkyl;C1-3Straight chained alkyl refer to carbon atom number be 1,2,3 straight chained alkyl, C1-6Alkyl refer to that carbon atom number is
1,2,3,4,5,6 linear or branched alkyl group, C1-6Alkoxy refer to carbon atom number be 1,2,3,4,5,6 linear chain or branched chain
Alkoxy, C1-6Acyl group refer to carbon atom number be 1,2,3,4,5,6 linear chain or branched chain acyl group, C1-6Acyloxy refer to carbon original
The linear chain or branched chain acyloxy that subnumber is 1,2,3,4,5,6, C1-6Alkylthio group refer to carbon atom number be 1,2,3,4,5,6 it is straight
Chain or branched alkylthio, C0-16Linear or branched alkyl group refer to carbon atom number be 0,1,2,3,4,5,6,7,8,9,10,11,
12,13,14,15,16 linear or branched alkyl group, C0-16Linear chain or branched chain acyl group refer to carbon atom number be 0,1,2,3,4,
5,6,7,8,9,10,11,12,13,14,15,16 linear chain or branched chain acyl group, C2-16Linear chain or branched chain alkenyl refer to carbon original
The linear chain or branched chain alkenyl that subnumber is 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16.
Specific embodiment
In order to which the present invention is furture elucidated, a series of embodiments are given below, these embodiments be entirely it is illustrative, it
Only be used to the present invention specifically describe, be not construed as limitation of the present invention.The synthesis road of intermediate 1d in embodiment
Line:
The synthetic route of compound 1~9 in embodiment:
Synthesize final product (compound numbers correspond to the compound numbers in embodiment)
The synthetic method of compound 1~9 in embodiment:
Method A: compound 1d (100mg, 0.23mmol) is dissolved in the dry methylene chloride of 50mL, sequentially adds HOBt
(37.6mg, 0.28mmol) and EDCI (53.0mg, 0.28mmol).After 20min is sufficiently stirred, alcohols or phenols chemical combination is added
4h is stirred at room temperature in object (1.2equiv), and TLC monitors raw material and disappears, and stops reaction.Reaction solution is concentrated under reduced pressure, and residue is with silica gel system
Slave board preparative separation (selecting suitable solvent according to different compounds) obtains target product.
Method B: compound 1d (100mg, 0.23mmol) is dissolved in the dry methylene chloride of 50mL, sequentially adds DMAP
(33.7mg, 0.28mmol) and EDCI (53.0mg, 0.28mmol), after 20min is sufficiently stirred, be added 1.2equiv alcohols or
4h is stirred at room temperature in phenolic compound, and TLC monitors reaction raw materials and disappears, and stops reaction.Reaction solution is concentrated under reduced pressure, and residue is with silica gel
It prepares plate preparative separation (selecting suitable solvent according to different compounds) and obtains target product.
Embodiment 1:
2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofurancarboxylic acid monooctyl ester (1)
It is synthesized according to method A, the alcohol compound of addition is n-octyl alcohol (1.2equiv), with petroleum ether: acetone (2: 1)
For solvent, silica gel prepares plate preparative separation and obtains target product, yield 32.9%.The physical and chemical parameter of compound 1 is as follows:
Compound 1: faint yellow brown solid, yield=32.9%.1H NMR(400MHz,acetone-d6):δ 7.50
(d, J=8.8Hz, 2H), 7.37 (d, J=2.4Hz, 1H), 7.14 (d, J=2.4Hz, 1H), 6.91 (d, J=8.8Hz, 2H),
6.55 (t, J=2.4Hz, 1H), 6.50 (d, J=2.4Hz, 2H), 3.94 (s, 3H), 3.81 (s, 3H), 3.79 (s, 6H),
3.62 (t, J=6.8Hz, 2H), 1.43-1.11 (m, 12H), 0.86 (t, J=6.8Hz, 3H);13C NMR(125MHz,
acetone-d6):δ167.73,162.22(2×C),160.90,158.36,156.13,152.22, 136.96,129.08(2
×C),127.51,123.66,121.64,116.87,114.75(2×C),113.23,108.53 (2×C),100.51,
99.30,65.65,56.43,55.73(2×C),55.64,32.53,29.96,29.86,29.01, 26.60,23.27,
14.34.(+)-ESI-MS m/z:547.3[M+H]+,569.3[M+Na]+,585.2[M+K]+. HR-ESI-MS m/z:
547.2677[M+H]+(calcd.for C33H39O7,547.2690).
Embodiment 2:
2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofurancarboxylic acid -2- furans
Methyl ester (2)
It is synthesized according to method A, the alcohol compound of addition is 2- furancarbinol, with petroleum ether: ethyl acetate: methylene chloride
It (5: 1: 2) is solvent, silica gel prepares plate preparative separation and obtains target product, yield 47.1%.The physical and chemical parameter of compound 2 is such as
Under:
Compound 2: beige solid, yield=54.4%.1H NMR(500MHz,acetone-d6):δ7.51(d, J
=9.0Hz, 2H), 7.48 (dd, J=2.0,1.0Hz, 1H), 7.37 (d, J=2.0Hz, 1H), 7.15 (d, J=2.0 Hz,
1H), 6.91 (d, J=9.0Hz, 2H), 6.59 (t, J=2.0Hz, 1H), 6.51 (d, J=2.0Hz, 2H), 6.36 (dd, J=
3.0,2.0Hz, 1H), 6.31 (d, J=3.0Hz, 1H), 4.58 (s, 2H), 3.93 (s, 3H), 3.81 (s, 3H), 3.80 (s,
6H);13C NMR(125MHz,acetone-d6):δ167.09,162.28(2×C),160.94, 158.36,156.11,
152.34,150.28,144.15,136.98,129.02(2×C),126.55,123.61,121.96, 116.82,114.77
(2×C),113.29,111.39,111.36,108.48(2×C),100.78,99.72,58.65, 56.47,55.75(2×
C),55.64.(+)-ESI-MS m/z:515.0[M+H]+,537.2[M+Na]+,553.1 [M+K]+.HR-ESI-MS m/z:
515.1684[M+H]+(calcd.for C30H27O8,515.1628).
Embodiment 3:
2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofurancarboxylic acid -2- phenyl
Ethyl ester (3)
Synthesize according to method B, the alcohol compound of addition is benzyl carbinol, with petroleum ether: acetone (2: 1) is solvent, silicon
Glue prepares plate preparative separation and obtains target product, yield 47.1%.The physical and chemical parameter of compound 3 is as follows:
Compound 3: beige solid, yield=73.5%.1H NMR(600MHz,acetone-d6) δ 7.51 (d, J=
9.0Hz, 2H), 7.36 (d, J=1.8Hz, 1H), 7.28~7.25 (m, 5H), 7.12 (d, J=1.8Hz, 1H), 6.91 (d, J
=9.0Hz, 2H), 6.60 (t, J=1.8Hz, 1H), 6.54 (d, J=1.8Hz, 2H), 3.92 (s, 3H), 3.83 (t, J=
7.8Hz, 2H), 3.81 (s, 3H), 3.78 (s, 6H), 2.62 (t, J=7.8Hz, 2H)13C NMR (150MHz,acetone-
d6):δ167.60,162.20(2×C),160.84,158.25,156.07,152.24, 138.63,137.10,129.59(2
×C),129.24(2×C),129.05(2×C),127.24,126.60,123.53, 121.63,116.73,114.71(2×
C),113.22,108.47(2×C),100.57,99.46,66.11,56.38, 56.74(2×C),55.60,35.15.(+)-
ESI-MS m/z:539.2[M+H]+,561.2[M+Na]+,577.2 [M+K]+.HR-ESI-MS m/z:539.2068[M+H]+
(calcd.for C33H31O7,539.2064).
Embodiment 4:
2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofurancarboxylic acid -2- methyl
Phenylester (4)
Synthesize according to method A, the alcohol compound of addition is ortho-methyl phenol, with petroleum ether: acetone (2: 1) is expansion
Agent, silica gel prepare plate preparative separation and obtain target product, yield 41.6%.The physical and chemical parameter of compound 4 is as follows:
Compound 4: faint yellow brown solid, yield=41.6%.1H NMR(500MHz,acetone-d6):7.50
(d, J=9.5Hz, 2H), 7.49 (d, J=3.0Hz, 1H), 7.48 (d, J=3.0Hz, 1H), 7.20 (dd, J=7.5,
2.5Hz, 1H), 7.15~7.08 (m, 2H), 6.89 (d, J=9.5Hz, 2H), 6.70 (dd, J=7.5,2.5Hz, 1H), 6.54
(d, J=2.5Hz, 2H), 6.34 (t, J=2.5Hz, 1H), 3.99 (s, 3H), 3.80 (s, 3H), 3.69 (s, 6H), 2.08 (s,
3H);13C NMR(125MHz,acetone-d6):δ164.76,162.13(2×C),160.93, 158.25,156.38,
152.76,150.15,137.12,131.53,130.80,128.97(2×C),127.22,126.52, 125.38,123.65,
122.81,122.71,117.16,114.77(2×C),114.66,109.22(2×C),100.58, 100.06,56.53,
55.64,55.58(2×C),16.36.(+)-ESI-MS m/z:525.2[M+H]+,547.2 [M+Na]+,563.2[M+K]+
.HR-ESI-MS m/z:525.1902[M+H]+(calcd.for C32H29O7, 525.1908).
Embodiment 5:
2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofurancarboxylic acid -4- acetyl
Base phenylester (5)
It is synthesized according to method B, the alcohol compound of addition is parahydroxyacet-ophenone, with petroleum ether: ethyl acetate: dichloromethane
Alkane (5: 1: 2) is solvent, and silica gel prepares plate preparative separation and obtains target product, yield 85.5%.The physical and chemical parameter of compound 5
It is as follows:
Compound 5: faint yellow solid, yield=44.5%.1H NMR(500MHz,acetone-d6):δ7.94(d, J
=9.0Hz, 2H), 7.51 (d, J=2.5Hz, 1H), 7.50 (d, J=9.0Hz, 2H), 7.42 (d, J=2.5Hz, 1H), 6.99
(d, J=9.0Hz, 2H), 6.90 (d, J=9.0Hz, 2H), 6.54 (d, J=2.5Hz, 2H), 6.29 (t, J=2.5Hz, 1H),
3.99(s,3H),3.81(s,3H),3.68(s,6H),2.58(s,3H);13C NMR(125 MHz,acetone-d6):δ
196.85,165.15,162.31(2×C),161.00,158.32,156.32,154.89, 152.85,136.99,135.58,
130.05(2×C),129.03(2×C),125.17,123.54,122.60,122.19 (2×C),116.92,114.80(2
×C),114.49,108.95(2×C),100.77,100.11,56.58,55.63(3 ×C),26.71.(+)-ESI-MS m/
z:553.0[M+H]+,575.1[M+Na]+,591.2[M+K]+. HR-ESI-MS m/z:553.1868[M+H]+(calcd.for
C33H29O8,553.1857).
Embodiment 6:
2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofurancarboxylic acid -4- fluorobenzene
Ylmethyl ester (6)
Synthesize according to method A, the alcohol compound of addition is p-fluorophenol, with petroleum ether: acetone (2: 1) is solvent,
Silica gel prepares plate preparative separation and obtains target product, yield 85.5%.The physical and chemical parameter of compound 6 is as follows:
Compound 6: beige solid, yield=49.4%.1H NMR(500MHz,acetone-d6):δ7.50(d, J
=9.0Hz, 2H), 7.39 (d, J=2.0Hz, 2H), 7.24 (d, J=8.5Hz, 1H), 7.20 (d, J=8.5Hz, 1H), 7.18
(d, J=2.0Hz, 1H), 7.09~7.04 (m, 2H), 6.90 (d, J=9.0Hz, 2H), 6.54 (t, J=2.0Hz, 1H),
6.50 (d, J=2.0Hz, 2H), 4.65 (s, 2H), 3.93 (s, 3H), 3.81 (s, 3H), 3.75 (s, 6H);13C NMR
(125MHz,acetone-d6):δ167.37,164.27,162.23(2×C),160.94, 158.37,156.16,152.38,
137.02,133.03,131.07,131.00,129.07(2×C),126.75,123.61, 121.86,116.84,115.92,
115.74,114.77(2×C),113.47,108.51(2×C),100.68,99.66, 66.22,56.46,55.69(2×
C),55.65.(+)-ESI-MS m/z:543.3[M+H]+,565.2[M+Na]+, 581.2[M+K]+.HR-ESI-MS m/z:
543.1813[M+H]+(calcd.for C32H28FO7,543.1814).
Embodiment 7:
2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofurancarboxylic acid -4- chlorobenzene
Base ester (7)
It is synthesized according to method B, the alcohol compound of addition is parachlorophenol (1.2equiv), with petroleum ether: acetone (2: 1)
For solvent, silica gel prepares plate preparative separation and obtains target product, yield 85.5%.The physical and chemical parameter of compound 7 is as follows:
Compound 7: pale yellow oily liquid, yield=85.5%.1H NMR(500MHz,acetone):δ7.50 (d,
J=9.0Hz, 2H), 7.49 (d, J=2.5Hz, 1H), 7.39 (d, J=2.5Hz, 1H), 7.34 (d, J=9.0 Hz, 2H),
6.89 (d, J=9.0Hz, 2H), 6.87 (d, J=8.9Hz, 2H), 6.53 (d, J=2.5Hz, 2H), 6.33 (t, J=2.5Hz,
1H),3.98(s,3H),3.80(s,3H),3.70(s,6H);13C NMR(125MHz, acetone-d6):δ165.36,
162.27(2×C),160.95,158.28,156.27,152.78,150.04,136.99, 131.11,129.60(2×C),
128.99(2×C),125.22,123.77(2×C),123.51,122.49,116.86, 114.77(2×C),114.37,
108.95(2×C),100.65,100.06,56.55,55.63(3×C). (+)-ESI-MS m/z:545.1[M+H]+,
567.2[M+Na]+,583.1[M+K]+.HR-ESI-MS m/z: 545.1356[M+H]+(calcd.for C31H26ClO7,
545.1362)..
Embodiment 8:
2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofurancarboxylic acid -4- bromobenzene
Ylmethyl ester (8)
Synthesize according to method A, the alcohol compound of addition is p bromophenol, with petroleum ether: acetone (2: 1) is solvent,
Silica gel prepares plate preparative separation and obtains target product, yield 47.1%.The physical and chemical parameter of compound 8 is as follows:
Compound 8: white solid, yield=47.1%.1H NMR(500MHz,acetone-d6): δ 7.50 (d, J=
8.5Hz, 2H), 7.48 (d, J=8.0Hz, 2H), 7.39 (d, J=2.0Hz, 1H), 7.19 (d, J=2.0Hz, 1H), 7.13
(d, J=8.0Hz, 2H), 6.90 (d, J=8.5Hz, 2H), 6.51 (t, J=2.0Hz, 1H), 6.48 (d, J=2.0Hz, 2H),
4.65(s,2H),3.94(s,2H),3.81(s,2H),3.73(s,6H);13C NMR(125 MHz,acetone-d6):δ
167.35,162.20(2×C),160.95,158.37,156.17,152.40,136.99, 136.26,132.17(2×C),
130.70(2×C),129.07(2×C),126.60,123.59,122.18,121.90, 116.83,114.77(2×C),
113.53,108.48(2×C),100.65,99.74,66.15,56.47,55.68(2× C),55.65.(+)-ESI-MS m/
z:641.1[M+K]+.HR-ESI-MS m/z:603.1017[M+H]+(calcd. for C32H28BrO7,603.1013).
Embodiment 9:
2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofurancarboxylic acid -1H- benzo
Triazole -1- base ester (9)
It is synthesized according to method B, the alcohol compound of addition is I-hydroxybenzotriazole monohydrate, with petroleum ether: acetic acid
Ethyl ester: methylene chloride (3: 1: 2) is solvent, and silica gel prepares plate preparative separation and obtains target product, yield 47.1%.Compound
9 physical and chemical parameter is as follows:
Compound 9: faint yellow solid, yield=20.5%.1H NMR(500MHz,acetone-d6):δ8.11(d, J
=8.0Hz, 1H), 7.84 (t, J=8.0Hz, 1H), 7.80 (d, J=8.0Hz, 1H), 7.65 (t, J=8.0Hz, 1H), 7.49
(d, J=2.5Hz, 1H), 7.47 (d, J=9.0Hz, 2H), 7.24 (d, J=2.5Hz, 1H), 6.87 (d, J=9.0Hz, 2H),
6.22 (d, J=2.0Hz, 2H), 5.60 (t, J=2.0Hz, 1H), 4.00 (s, 3H), 3.79 (s, 3H), 3.57 (s, 6H);13C
NMR(125MHz,acetone):δ164.82,161.59(2×C),161.02, 158.67,155.37,152.16,134.74,
133.80,133.40,132.89,128.73(2×C),127.70,126.70, 123.20,122.59,116.25,116.13,
115.86,114.83(2×C),112.96,107.29(2×C),100.00, 99.74,56.62,55.62,55.32.(+)-
ESI-MS m/z:551[M+H]+,574[M+Na]+,590[M+K]+; HR-ESI-MS m/z:574.1561[M+Na]+
(calcd.for C31H25N3NaO7,574.1585).
The method of methoxyl group is removed in embodiment 10,11:
2,3- diaryl substitute amide derivatives (about 70mg) are dissolved in the dry methylene chloride of 30mL, are cooled to -50
℃.It is vigorously stirred down, is slowly dropped into BBr3Dichloromethane solution [BBr3(12equiv, 1mmol/L in DCM) is dissolved in 15mL
In dry methylene chloride].It is added dropwise, keeps -50 DEG C of stirring 2h, be successively to slowly warm up to -25 DEG C, -10 DEG C and 0 DEG C, and -
2h is stirred respectively at 25 DEG C, -10 DEG C and 0 DEG C.Overnight, TLC monitors end of reaction for room temperature reaction.Reaction solution is cooled to -50 DEG C, drop
Enter 6mL analysis methanol, reaction solution is with the dilution of 100mL ethyl acetate, and 50mL washing, saturated common salt washing, water phase is with ethyl acetate
Back extraction, organic phase merge, and anhydrous sodium sulfate is dry, are concentrated under reduced pressure, and residue is with the mixed solvent of ethyl acetate and methanol (or third
The mixed solvent of ketone and methanol) dissolution, plate is prepared with silica gel and separates to obtain crude product, crude product further obtains target chemical combination with gel-purified
Object sterling.Gel-purified is needed once in a while usually using methanol as eluant, eluent with chloroform: methanol (3: 7) is eluted.
Embodiment 10:
2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzofurancarboxylic acid (10)
Compound 1d is raw material, is reacted according to the method for removing methoxyl group.With methylene chloride: methanol (10: 1) is
Solvent, silica gel prepare plate separation and are prepared into compound 10.
Compound 10: light khaki solid (20.6mg, 23.7%).1H NMR(500MHz,CD3OD): δ 7.35 (d, J=
9.0Hz, 2H), 6.89 (d, J=2.0Hz, 1H), 6.83 (d, J=2.0Hz, 1H), 6.68 (d, J=9.0 Hz, 2H), 6.34
(d, J=2.0Hz, 2H), 6.24 (s, 1H)13C NMR(150MHz,CD3OD 6):δ 175.73,159.25(2×C),
158.38,156.55,155.92,151.40,136.94,136.85,129.20(2×C), 123.97,119.88,117.51,
115.99(2×C),111.55,110.10,103.08,98.26.(-)-ESI-MS m/z: 377[M-H]-;HR-ESI-MS
m/z:379.0812[M+H]+(calcd.for C21H15O7,379.0812).
Embodiment 11:
2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzofurancarboxylic acid methyl esters (11)
Compound 1c is raw material, is reacted according to the method for removing methoxyl group.With methylene chloride: methanol (20: 1) is
Solvent, silica gel prepare plate separation and are prepared into compound 11.
Compound 11: hazel-color solid (44.4mg, 12.7%).1H NMR(500MHz,acetone-d6):δ 8.56
(s, 3H), 7.44 (d, J=9.0Hz, 2H), 7.18 (d, J=2.0Hz, 1H), 7.12 (d, J=2.0Hz, 1H), 6.80 (d, J
=9.0Hz, 2H), 6.41 (t, J=2.0Hz, 1H), 6.30 (d, J=2.0Hz, 2H), 3.25 (s, 3H)13C NMR
(125MHz,acetone):δ168.09,159.78(2×C),158.62,156.11,155.68, 151.96,137.39,
129.06(2×C),126.68,122.85,121.49,116.59,116.10(2×C),113.82, 109.07,102.48,
101.33,51.39.(+)-ESI-MS m/z 414.9[M+Na]+,431.0[M+K]+.HR- ESI-MS m/z:415.0794[M
+Na]+(calcd.for C22H16NaO7,415.0788).
The synthetic route of compound 12~26 in embodiment:
Synthesize final product (compound numbers correspond to the compound numbers in embodiment)
The synthetic method of compound 12~26 in embodiment:
Synthetic method A: compound 1d (100mg, 0.23mmol) is dissolved in the dry methylene chloride of 50mL, sequentially adds
HOBt (37.6mg, 0.28mmol) and EDCI (53.0mg, 0.28mmol), is sufficiently stirred 20 min.Amine is added in reaction solution
4h is stirred at room temperature in compound (1.2equiv), and TLC monitors reaction raw materials and disappears, and stops reaction.Reaction solution is concentrated under reduced pressure, gained
Residue prepares plate separation (solvent is selected according to different situations) with silica gel and obtains corresponding product.
Synthetic method B: compound 1d (100mg, 0.23mmol) is dissolved in the dry methylene chloride of 50mL, sequentially adds
After 20min is sufficiently stirred, aminated compounds is added in DMAP (33.7mg, 0.28mmol) and EDCI (53.0mg, 0.28mmol)
4h is stirred at room temperature in (1.2equiv), and TLC monitors raw material and disappears, and stops reaction.Reaction solution is concentrated under reduced pressure, and residue is with silica gel system
Slave board separates (solvent is selected according to different situations) and obtains corresponding product.
Embodiment 12:
N- methyl -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofuran formyl
Amine (12)
The aminated compounds of reference method A synthesis, addition is methylamine, with methylene chloride: methanol (40: 1) is solvent,
Silica gel prepares plate preparative separation and obtains, yield 65.7%.The physical and chemical parameter of compound 12 is as follows:
Khaki solid, yield=65.7%.1H NMR(500MHz,acetone-d6): δ 7.51 (d, J=8.5
Hz, 2H), 7.22 (d, J=1.5Hz, 1H), 6.90 (d, J=8.5Hz, 2H), 6.88 (d, J=1.5Hz, 1H), 6.67 (d, J
=4.0Hz, 1H), 6.52 (s, 3H), 3.90 (s, 3H), 3.81 (s, 3H), 3.79 (s, 6H), 2.33 (d, J=4.5Hz, 3H)
;13C NMR(125MHz,acetone-d6):δ167.79,162.13(2×C),160.76, 158.67,155.84,151.28,
136.12,133.03,128.78(2×C),123.85,120.63,116.70,114.79 (2×C),111.63,108.65(2
×C),100.94,97.43,56.30,55.70(2×C),55.63,26.05. (+)-ESI-MS m/z:470.2[M+Na]+,
486.1[M+K]+.HR-ESI-MS m/z:448.1761[M+H]+ (calcd.for C26H26NO6,448.1755).
Embodiment 13:
N- propyl -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofuran formyl
Amine (13)
Synthesize according to method B, the aminated compounds of addition is n-propylamine, with petroleum ether: acetone (2: 1) is solvent, silicon
Glue prepares plate preparative separation and obtains, yield 84.9%.The physical and chemical parameter of compound 13 is as follows:
Compound 13: khaki solid, yield=84.9%.1H NMR(500MHz,acetone-d6):δ7.50
(d, J=9.0Hz, 2H), 7.22 (d, J=2.5Hz, 1H), 6.90 (d, J=9.0Hz, 2H), 6.89 (d, J=2.5 Hz, 1H),
6.70 (brs, 1H), 6.54 (d, J=2.0Hz, 2H), 6.52 (t, J=2.0Hz, 1H), 3.90 (s, 3H), 3.81 (s, 3H),
3.78 (s, 6H), 2.75 (dd, J=13.0,6.5Hz, 2H), 1.23-1.31 (m, 2H), 0.78 (t, J=7.5Hz, 3H);13C
NMR(125MHz,acetone-d6):δ167.37,162.11(2×C),160.72, 158.63,155.85,151.29,
136.13,133.24,128.80(2×C),123.84,120.59,116.83(2×C), 114.77,111.78,108.79(2
×C),100.85,97.31,56.30,55.67(2×C),55.63,42.08,22.88, 11.83.(+)-ESI-MS m/z:
476.1[M+H]+,498.1[M+Na]+,514.0[M+K]+.HR-ESI-MS m/z:476.2025[M+H]+(calcd.for
C28H30NO6,476.2068).
Embodiment 14:
N- dodecyl -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofuran
Formamide (14)
The aminated compounds of reference method A synthesis, addition is lauryl amine, with petroleum ether: acetone (2: 1) is solvent, silicon
Glue prepares plate preparative separation and obtains, yield 96.2%.The physical and chemical parameter of compound 14 is as follows:
Compound 14: reddish tan solid, yield=96.2%.1H NMR(500MHz,acetone-d6):δ7.49
(d, J=8.5Hz, 2H), 7.22 (d, J=2.5Hz, 1H), 6.90 (d, J=8.5Hz, 2H), 6.89 (d, J=2.5 Hz, 1H),
6.67 (t, J=5.0Hz, 1H), 6.54 (d, J=2.5Hz, 2H), 6.52 (t, J=2.5Hz, 1H), 3.90 (s, 3H), 3.81
(s, 3H), 3.79 (s, 6H), 2.77 (t, J=7.0Hz, 2H), 1.28 (m, 20H), 0.87 (t, J=7.0Hz, 3H);13C NMR
(125MHz,acetone-d6):δ167.34,162.11(2×C),160.75,158.64, 155.87,151.33,136.14,
133.24,128.83(2×C),123.87,120.54,116.82,114.77(2×C), 111.82,108.76(2×C),
100.98,97.33,56.31,55.69(2×C),55.63,40.39,32.65,30.40- 30.36(5×C),30.09(2×
C),27.85,23.33,14.36.(+)-ESI-MS m/z:602.4[M+H]+, 624.4[M+Na]+,640.3[M+K]+.HR-
ESI-MS m/z:602.3481[M+H]+(calcd.for C37H48NO6,602.3476).
Embodiment 15:
N- (3- dimethylamino -1- propyl) -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxy
Base -4- benzofuran carboxamides (15)
The aminated compounds of reference method B synthesis, addition is N'N- dimethyl -1,3- propane diamine, with chloroform: methanol (6:
It 1) is solvent, silica gel prepares plate preparative separation and obtains, yield 95.0%.The physical and chemical parameter of compound 15 is as follows:
Compound 15: beige solid, yield=95.0%.1H NMR(500MHz,acetone-d6):δ7.50 (d,J
=9.0Hz, 1H), 7.22 (s, 1H), 7.14 (s, 1H), 6.91 (s, 1H), 6.90 (d, J=9.0Hz, 2H), 6.55 (s, 2H),
6.52 (s, 1H), 3.91 (s, 3H), 3.81 (s, 3H), 3.79 (s, 6H), 2.90 (dd, J=12.5,6.5 Hz, 2H), 2.33
(s, 6H), 1.61-1.46 (t, J=6.5Hz, 2H), 0.87 (d, J=6.5Hz, 2H) (+)-ESI-MS m/z:519.3 [M+
H]+.
Embodiment 16:
[N-2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofuran formoxyl] egg
Propylhomoserin methyl esters (16)
Reference method B synthesis, compound 1d (100mg, 0.23mmol) are dissolved in the dry methylene chloride of 50mL, successively plus
Enter DMAP (33.7mg, 0.28mmol), EDCI (53.0mg, 0.28mmol) and DIPEA (114 μ L, 0.69mmol), stirs
After 20min, the L-Methionine methyl esters of 1.2equiv is added.4h is stirred at room temperature in reaction solution, and TLC monitors reaction raw materials and disappears, stops
Reaction.Reaction solution is concentrated under reduced pressure, and residue is with petroleum ether: acetone (3: 2) prepares plate preparative separation for solvent silica gel and obtains target
Product.
Compound 16: faint yellow solid, yield=38.9%.1H NMR(500MHz,acetone-d6):δ7.48(d, J
=8.8Hz, 2H), 7.26 (d, J=2.2Hz, 1H), 7.25 (s, 1H), 6.92 (d, J=2.3Hz, 1H), 6.90 (d, J=
8.8Hz, 2H), 6.52 (s, 3H), 4.12 (q, J=6.7Hz, 1H), 3.92 (s, 3H), 3.81 (s, 3H), 3.79 (s, 6H),
3.69 (s, 3H), 2.35 (dt, J=9.1,6.4Hz, 2H), 2.04 (s, 3H), 1.75-1.68 (m, 2H)13C NMR
(125MHz,CD3OD):δ172.56,167.79,161.86(2×C),160.73,158.49, 155.84,151.52,
135.76,132.00,128.90(2×C),123.74,120.46,116.77,114.73(2×C), 112.04,108.80,
100.73,97.48,56.30,55.61(2×C),53.10,53.00,52.34,31.94,30.52, 15.08.(+)-ESI-
MS m/z:580.0[M+H]+,602.1[M+Na]+,618.1[M+K]+.HR-ESI-MS m/z:580.2009[M+H]+
(calcd.for C31H34O8S,580.2000).
Embodiment 17:
N- cyclopenta -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofuran first
Amide (17)
The aminated compounds of reference method A synthesis, addition is cyclopentamine, with methylene chloride: methanol (30: 1) is solvent,
Silica gel prepares plate preparative separation and obtains, yield 92.1%.
The physical and chemical parameter of compound 17 is as follows:
Compound 17: khaki solid, yield=92.1%.1H NMR(500MHz,acetone-d6):δ7.48
(d, J=9.0Hz, 2H), 7.20 (d, J=2.5Hz, 1H), 6.90 (d, J=9.0Hz, 2H), 6.86 (d, J=2.5 Hz, 1H),
6.74 (d, J=6.0Hz, 1H), 6.53 (d, J=2.0Hz, 2H), 6.52 (t, J=2.0Hz, 1H), 3.90 (s, 3H), 3.81
(s, 3H), 3.78 (s, 6H), 3.72 (q, J=6.5Hz, 1H), 1.71-1.62 (m, 2H), 1.57-1.50 (m, 2H), 1.48-
1.38(m,2H),1.25–1.16(m,2H);13C NMR(125MHz, acetone-d6):δ167.25,162.05(2×C),
160.71,158.58,155.83,151.25,136.03,133.43, 128.83(2×C),123.88,120.46,116.96,
114.74(2×C),111.89,108.85(2×C),100.91, 97.13,56.29,55.64(3×C),52.23,33.04,
29.84(2×C),24.45(2×C).(+)-ESI-MS m/z: 502.2[M+H]+,524.2[M+Na]+,540.5[M+K]+
.HR-ESI-MS m/z:502.2242[M+H]+ (calcd.for C30H32NO6,502.2224).
Embodiment 18:
N- (2- furyl base) -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzo
Furoylamide (18)
The aminated compounds of reference method B synthesis, addition is furylamine, with petroleum ether: acetone (5: 2) is solvent
After silica gel prepares plate preparative separation, then obtained with acetone recrystallization.
The physical and chemical parameter of compound 18 is as follows:
Compound 18: white chunks crystallization, yield=88.1%.1H NMR(500MHz,acetone-d6):δ7.52
(d, J=9.0Hz, 2H), 7.39 (d, J=2.0Hz, 1H), 7.24 (d, J=2.0Hz, 1H), 7.11 (t, J=5.0 Hz, 1H),
6.92 (d, J=2.0Hz, 1H), 6.91 (d, J=9.0Hz, 1H), 6.57 (d, J=2.0Hz, 2H), 6.55 (t, J=2.0Hz,
1H), 6.30 (dd, J=3.0,2.0Hz, 1H), 6.13 (d, J=3.0Hz, 1H), 3.91 (d, J=5.8Hz, 2H), 3.90 (s,
3H),3.81(s,3H),3.80(s,6H);13C NMR(125MHz, acetone-d6):δ167.21,162.16(2×C),
160.76,158.62,155.83,152.76,151.36,142.71, 136.17,132.36,128.75(2×C),123.81,
120.77,116.70,114.78(2×C),111.72,111.12, 108.71(2×C),107.70,101.03,97.66,
56.32,55.70(2×C),55.62,37.00.(+)-ESI-MS m/z:514.2[M+H]+,536.2[M+Na]+,552.5[M+
K]+.HR-ESI-MS m/z:514.1859[M+H]+ (calcd.for C30H28NO7,514.1860).
Embodiment 19:
N- (phenyl methyl) -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzo furan
It mutters formamide (19)
Reference method A synthesis, the aminated compounds of addition are benzylamine.Petroleum ether: ethyl acetate: methylene chloride (3: 1: 2)
It prepares plate preparative separation for solvent with silica gel to obtain, yield 93.2%.
The physical and chemical parameter of compound 19 is as follows:
Compound 19: beige solid, yield=93.2%.1H NMR(500MHz,acetone-d6):δ7.51 (d,J
=9.0Hz, 2H), 7.26 (t, J=7.0Hz, 2H), 7.24 (d, J=2.5Hz, 1H), 7.20 (d, J=7.0 Hz, 1H), 7.16
(d, J=7.0Hz, 2H), 6.95 (d, J=2.5Hz, 1H), 6.90 (d, J=9.0Hz, 2H), 6.59 (d, J=2.5Hz, 2H),
6.57 (t, J=2.5Hz, 1H), 3.96 (d, J=5.8Hz, 2H), 3.90 (s, 3H), 3.81 (s, 3H), 3.80 (s, 6H);13C
NMR(125MHz,acetone-d6):δ167.43,162.17(2×C), 160.76,158.63,155.89,151.41,
139.80,136.21,132.71,129.09(2×C),128.81(2×C), 128.48(2×C),127.67,123.85,
120.72,116.79,114.78(2×C),111.92,108.83(2×C), 101.10,97.55,56.33,55.72(2×
C),55.63,43.94.(+)-ESI-MS m/z:522.5[M-H]-,546.2 [M+Na]+.HR-ESI-MS m/z:524.2077
[M+H]+(calcd.for C32H30NO6,524.2068).
Embodiment 20:
N- methyl-N- (phenyl methyl) -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4-
Benzofuran carboxamides (20)
Reference method B synthesis, the aminated compounds of addition are N- benzylmethylamine.With petroleum ether: ethyl acetate: methylene chloride
=3:1:2 is that solvent carries out preparing plate and purifies to obtain, yield 71.8%.
Compound 20: beige solid (a pair of of enantiomter), yield=71.8%.1H NMR(500MHz,
acetone-d6): δ 7.55 (d, J=8.9Hz, 2H), 7.54 (d, J=8.9Hz, 2H), 7.16-7.34 (m, 8H), 7.03-
7.08 (m, 2H), 6.92 (d, J=8.8Hz, 2H), 6.84 (d, J=2.3Hz, 1H), 6.80 (d, J=2.2 Hz, 1H), 6.65
(d, J=2.3Hz, 2H), 6.62 (d, J=2.3Hz, 2H), 6.60 (t, J=2.3Hz, 1H), 6.56 (t, J=2.3Hz, 1H),
4.97 (d, J=14.3Hz, 1H), 4.41 (d, J=15.9Hz, 1H), 3.92 (s, 3H), 3.86 (s, 3H), 3.84 (s, 6H),
3.83 (s, 6H), 3.82 (s, 6H), 3.59 (d, J 22=15.9Hz, 1H), 3.13 (d, J=14.6Hz, 1H), 2.42 (s,
3H),2.39(s,3H).13C NMR(125MHz,acetone-d6): δ168.07,167.98,161.13(2×C),161.04
(2×C),159.91(2×C),158.23,158.11, 154.77,154.58,150.57,137.38,137.05,134.16,
134.09,130.88,130.65,128.53(2×C), 128.45(2×C),127.95(2×C),127.90(2×C),
127.88(2×C),127.29,127.08,126.95 (2×C),122.80,119.30,118.98,115.77,113.91(4
×C),110.38,110.12,107.78(4×C), 100.57,100.52,95.93,95.86,55.43,55.36,54.88
(2×C),54.86(2×C),54.74,54.22, 54.07,49.24,35.13,30.96.(+)-ESI-MS m/z:538.2
[M+H]+,560.2[M+Na]+,576.2 [M+K]+.HR-ESI-MS m/z:538.2222[M+H]+(calcd.for
C33H32NO6,538.2224).
Embodiment 21:
N- (4- aminomethyl phenyl) -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzo
Furoylamide (21)
Reference method B synthesis, the aminated compounds of addition are para-totuidine.With petroleum ether: acetone (2: 1) is solvent
Silica gel prepares plate preparative separation and obtains, yield 63.4%.
The physical and chemical parameter of compound 21 is as follows:
Compound 21: white solid, yield=63.4%.1H NMR(500MHz,acetone-d6):δ8.64(s,
1H), 7.53 (d, J=9.0Hz, 2H), 7.33 (d, J=8.5Hz, 2H), 7.28 (d, J=2.5Hz, 1H), 7.01 (d, J=
2.5Hz, 1H), 6.99 (d, J=8.5Hz, 2H), 6.90 (d, J=9.0Hz, 2H), 6.50 (d, J=2.5Hz, 2H), 6.05
(t, J=2.5Hz, 1H), 3.93 (s, 3H), 3.80 (s, 3H), 3.61 (s, 6H), 2.28 (s, 3H)13C NMR(125MHz,
acetone-d6):δ168.82,161.59(2×C),161.02,158.67,155.37,152.16, 134.74,133.80,
133.40(2×C),132.89,128.73(2×C),127.70(2×C),126.70,123.20, 122.59,116.25,
116.13,115.87,114.83(2×C),112.96,107.29(2×C),99.99,99.74, 56.22,55.62,55.32
(2×C),29.50.(+)-ESI-MS m/z:524.2[M+H]+,546.2[M+Na]+, 562.2[M+K]+.HR-ESI-MS m/
z:524.2061[M+H]+(calcd.for C32H30NO6,524.2068).
Embodiment 22:
N- (4- chlorphenyl) -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzo furan
It mutters formamide (22)
Reference method B synthesis, the aminated compounds of addition are parachloroanilinum.With petroleum ether: acetone (2: 1) is solvent
Silica gel prepares plate preparative separation and obtains, yield 53.5%.
The physical and chemical parameter of compound 22 is as follows:
Compound 22: white solid, yield=53.5%.1H NMR(500MHz,acetone-d6)δ8.85(s, 1H),
7.52 (d, J=9.0Hz, 2H), 7.47 (d, J=9.0Hz, 2H), 7.29 (s, 1H), 7.18 (d, J=9.0Hz, 2H), 7.01
(s, 1H), 6.89 (d, J=9.0Hz, 2H), 6.47 (s, 2H), 6.03 (d, J=2.0Hz, 1H), 3.92 (s, 3H), 3.79 (s,
3H),3.62(s,6H);13C NMR(125MHz,acetone-d6):δ166.04,162.11 (2×C),160.81,158.72,
155.80,151.45,138.53,135.71,132.19,128.72(2×C),128.70 (2×C),128.32,123.68,
121.21(2×C),121.11,116.61,114.81(2×C),111.77,108.51 (2×C),100.00,98.20,
56.43,55.63,55.39.(+)-ESI-MS m/z:544.1[M+H]+,566.2 [M+Na]+,582.2[M+K]+.HR-ESI-
MS m/z:544.1529[M+H]+(calcd.for C31H27ClNO6, 544.1521).
Embodiment 23:
N- (4- Chlorophenylmethyl) -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzene
And furoylamide (23)
Reference method A synthesis, the aminated compounds of addition are 4- chlorobenzylamine.Petroleum ether: ethyl acetate: methylene chloride (3: 1
: 2) plate preparative separation is prepared with silica gel for solvent and obtained.
The physical and chemical parameter of compound 23 is as follows:
Compound 23: white solid, yield=69.3%.1H NMR(500MHz,acetone-d6): δ 7.51 (d, J=
8.5Hz, 2H), 7.28 (d, J=8.0Hz, 2H), 7.25 (d, J=1.5Hz, 1H), 7.17 (d, J=8.0Hz, 2H), 6.95
(d, J=1.5Hz, 1H), 6.91 (d, J=8.5Hz, 2H), 6.57 (d, J=1.5Hz, 1H), 6.55 (t, J=1.5Hz, 1H),
3.96 (d, J=6.0Hz, 2H), 3.91 (s, 3H), 3.81 (s, 3H), 3.79 (s, 6H);13C NMR(125MHz,acetone-
d6):δ167.53,162.13(2×C),160.77,158.63,155.89,151.45, 138.83,136.17,132.94,
132.49,130.22(2×C),129.09(2×C),128.80(2×C),123.80, 120.71,116.74,114.78(2
×C),111.97,108.82(2×C),101.05,97.60,56.33,55.70(2× C),55.63,43.25.(+)-ESI-
MS m/z:558.2[M+H]+,580.2[M+Na]+,596.2[M+K]+. HR-ESI-MS m/z:558.1695[M+H]+
(calcd.for C32H29ClNO6,558.1678).
Embodiment 24:
N- [2- (1H- indol-3-yl) ethyl] -2- (4- methoxyphenyl) -3- (3,5- Dimethoxyphenyl) -6- methoxy
Base -4- benzofuran carboxamides (24)
It is synthesized according to method A, the aminated compounds of addition is tryptamines (β-indolecthanamine), with petroleum ether: acetone (6: 1)
The isolated target product of silica gel column chromatography is carried out for eluant, eluent.
The physical and chemical parameter of compound 24 is as follows:
Compound 24: faint yellow solid, yield=86.6%.1H NMR(500MHz,acetone-d6):δ9.95 (s,
1H), 7.56 (d, J=8.0Hz, 1H), 7.51 (d, J=8.5Hz, 2H), 7.35 (d, J=8.0Hz, 1H), 7.22 (d, J=
2.0Hz, 1H), 7.10 (d, J=2.0Hz, 1H), 7.07 (t, J=8.0Hz, 1H), 7.02 (t, J=8.0Hz, 1H), 6.91
(s, 1H), 6.90 (d, J=8.5Hz, 2H), 6.85 (t, J=5.0Hz, 1H), 6.58 (d, J=2.0Hz, 2H), 6.51 (t, J
=2.0Hz, 1H), 3.90 (s, 3H), 3.81 (s, 3H), 3.76 (s, 6H), 3.18-3.11 (m, 2H), 2.73-2.68 (m,
2H);13C NMR(125MHz,acetone-d6):δ167.43,162.13(2×C), 160.75,158.62,155.88,
151.36,137.69,136.22,133.14,128.83(2×C),128.57,123.88, 123.09,122.08,120.62,
119.40,119.36,116.85,114.77(2×C),113.51,112.10,111.76, 108.88(2×C),101.03,
97.46,56.31,55.71(2×C),55.63,41.12,25.68.(+)-ESI-MS m/z:577.2[M+H]+,599.1[M+
Na]+.HR-ESI-MS m/z:577.2326[M+H]+(calcd.for C35H33N2O6,577.2333).
Embodiment 25:
N- [2- (5- methoxyl group -1H- indol-3-yl) ethyl] -2- (4- methoxyphenyl) -3- (3,5- dimethoxy benzene
Base) -6- methoxyl group -4- benzofuran carboxamides (25)
It is synthesized according to method B.The aminated compounds of addition is 2- (5- methoxyl group -1H- indol-3-yl) ethamine.With petroleum
Ether: acetone (2: 1) prepares plate preparative separation for solvent silica gel and obtains.
The physical and chemical parameter of compound 25 is as follows:
Compound 25: faint yellow solid, yield=66.0%.1H NMR(500MHz,acetone-d6):δ9.79 (s,
1H), 7.51 (d, J=9.0Hz, 2H), 7.24 (d, J=8.5Hz, 1H), 7.22 (d, J=2.5Hz, 1H), 7.08 (d, J=
2.5Hz, 1H), 7.05 (d, J=2.5Hz, 1H), 6.91 (d, J=2.5Hz, 1H), 6.90 (d, J=9.0,2H), 6.83 (t, J
=5.5Hz, 1H), 6.74 (dd, J=8.5,2.5Hz, 1H), 6.58 (d, J=2.5Hz, 2H), 6.51 (t, J=2.5Hz,
1H), 3.90 (s, 3H), 3.81 (s, 6H), 3.75 (s, 6H), 3.18-3.09 (m, 2H), 2.66 (t, J=7.5Hz, 2H);13C
NMR(125MHz,acetone-d6):δ167.48,162.12(2×C), 160.74,158.61,155.87,154.68,
151.34,136.22,133.08,132.79,128.82(2×C),123.86, 123.76,120.61,116.82(2×C),
113.29,112.71,112.38,111.77,108.80(2×C),101.19, 101.08,97.47,56.30,55.93,
55.70(2×C),55.63,41.05,25.70.(+)-ESI-MS m/z:607.1 [M+H]+,629.1[M+Na]+,645.0[M
+K]+.HR-ESI-MS m/z:607.2430[M+H]+(calcd.for C36H35N2O7,607.2439).
Embodiment 26:
N- [2- (4- methoxyphenyl)] -3- (3,5- Dimethoxyphenyl) -6- methoxyl group -4- benzofuran formoxyl]
D-trp methyl esters (26)
Synthesize according to method B, the aminated compounds of addition is D-trp, with petroleum ether: acetone (2: 1) is solvent
Silica gel prepares plate preparative separation and obtains.
Compound 26: pale yellow oily liquid, yield=48.4%.1H NMR(500MHz,acetone-d6):δ 7.53
(d, J=7.2Hz, 1H), 7.51 (d, J=9.0Hz, 2H), 7.34 (d, J=8.0Hz, 1H), 7.23 (d, J=2.2Hz, 1H),
7.09 (s, 1H), 7.07 (td, J=8.0,1.0Hz, 1H), 7.07 (td, J=7.5,1.1Hz, 1H), 6.90 (d, J=
7.7Hz, 2H), 6.89 (d, J=2.2Hz, 1H), 6.55 (d, J=2.3Hz, 2H), 6.51 (t, J=2.3Hz, 1H), 4.31
(td, J=7.0,4.9Hz, 1H), 3.89 (s, 3H), 3.80 (s, 3H), 3.75 (s, 6H), 3.54 (s, 3H), 3.12 (dd, J=
14.5,7.4Hz, 1H), 3.03 (dd, J=14.5,4.9Hz, 1H)13C NMR(125 MHz,acetone-d6):δ172.49,
167.32,161.90(2×C),160.74,158.51,155.81,151.45, 137.40,135.90,132.06,128.86
(2×C),128.71,124.32,123.75,122.11,120.60,119.50, 119.31,116.74,114.73(2×C),
112.12,111.69,110.35,108.75(2×C),100.95,97.70, 56.33,55.60(3×C),54.69,
52.13,28.07.(+)-ESI-MS m/z:635.1[M+H]+,657.1 [M+Na]+,673.1[M+K]+.HR-ESI-MS m/
z:635.2395[M+H]+(calcd.for C37H35N2O8, 635.2388).
The synthetic route of compound 27~36 in embodiment:
Synthesize final product (compound numbers correspond to the compound numbers in embodiment)
Compound 27~36 in embodiment are synthesized referring to the method for embodiment 10,11:
Embodiment 27:
N- methyl -2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzofuran carboxamides (27)
Compound 27: hazel-color solid (28.0mg, 45.8%).1H NMR(500MHz,CD3OD): δ 7.40 (d, J=
8.5Hz, 2H), 7.00 (d, J=2.5Hz, 1H), 6.78 (d, J=2.5Hz, 1H), 6.70 (d, J=8.5 Hz, 2H), 6.30
(t, J=2.0Hz, 1H), 6.28 (d, J=2.0Hz, 1H), 2.40 (s, 3H);13C NMR(125 MHz,CD3OD):δ171.07,
160.13(2×C),158.85,156.41,156.36,151.94,136.82, 131.32,129.07(2×C),123.29,
120.62,116.23,116.16(2×C),112.05,109.58(2×C), 102.98,99.89,26.29.(+)-ESI-MS
m/z:392[M+H]+,414[M+Na]+;(-)-ESI-MS m/z: 390[M-H]-;HR-ESI-MS m/z:392.1126[M+
H]+(calcd.for C22H18NO6,392.1129).
Embodiment 28:
N- dodecyl -2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzofuran carboxamides
(28)
Compound 28: khaki solid (38.2mg, 52.77%).1H NMR(500MHz,acetone-d6):δ8.81(s,
1H), 8.64 (s, 1H), 8.46 (s, 2H), 7.39 (d, J=9.0Hz, 2H), 6.96 (d, J=2.0Hz, 1H), 6.92 (d, J=
2.0Hz, 1H), 6.79 (d, J=9.0Hz, 2H), 6.61 (t, J=5.5Hz, 1H), 6.37 (t, J=2.0Hz, 1H), 6.33
(d, J=2.0Hz, 2H), 2.84 (dd, J=13.0,7.0Hz, 2H), 1.58-1.09 (m, 20H), 0.87 (t, J=7.0Hz,
3H);13C NMR(125MHz,acetone-d6):δ168.01,159.99 (2×C),158.41,155.88,155.84,
151.21,136.32,132.16,128.91(2×C),123.06,119.97, 116.22,116.09(2×C),112.53,
109.32(2×C),103.02,99.48,40.60,32.64,30.41, 30.38(2×C),30.34,29.58,27.88,
23.33,14.36.(+)-ESI-MS m/z:546[M+H]+,568 [M+Na]+;(-)-ESI-MS m/z:544[M-H]-,580
[M+Cl]-;HR-ESI-MS m/z:546.2855 [M+H]+(calcd.for C33H40NO6,546.2850).
Embodiment 29:
N- (dimethylamino -1- propyl) -2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzo furan
It mutters formamide (29)
Compound 29: faint yellow solid (33.6mg, 53.9%).1H NMR(500MHz,CD3OD): δ 7.37 (d, J=
8.5Hz, 2H), 7.02 (d, J=2.0Hz, 1H), 6.80 (d, J=2.0Hz, 1H), 6.70 (d, J=8.5 Hz, 2H), 6.30
(s, 3H), 2.92 (t, J=7.5Hz, 2H), 2.61 (t, J=7.5Hz, 2H), 2.53 (s, 6H), 2.18 (dd, J=15.0,
7.5Hz,2H);13C NMR(150MHz,CD3OD):δ171.14,160.05(2× C),158.90,156.49,156.31,
152.28,130.98,130.84,129.87,129.16(2×C),123.17, 120.47,116.19(2×C),112.38,
109.83(2×C),103.04,100.09,53.72,43.81,37.91, 33.06,28.11.(+)-ESI-MS m/z:463
[M+H]+,485[M+Na]+;(-)-ESI-MS m/z:461[M-H]-; HR-ESI-MS m/z:463.1872[M+H]+
(calcd.for C26H27N2O6,463.1864).
Embodiment 30:
N- cyclopenta -2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzofuran carboxamides
(30)
Compound 30: hazel-color solid (50.9mg, 81.8%).1H NMR(500MHz,CD3OD): δ 7.35 (d, J=
8.5Hz, 2H), 7.03 (s, 1H), 6.98 (d, J=1.5Hz, 1H), 6.75 (d, J=1.5Hz, 1H), 6.69 (d, J=
8.5Hz, 2H), 6.29 (s, 3H), 3.72 (quint, J=7.0Hz, 1H), 1.76 (dt, J=13.0,7.0Hz, 1H), 1.65-
1.53 (m, 1H), 1.52-1.41 (m, 1H), 1.22 (td, J=13.0,7.0Hz, 1H);1H NMR (500MHz,acetone-
d6): δ 7.38 (d, J=9.0Hz, 2H), 7.01 (d, J=2.0Hz, 1H), 6.86 (d, J=2.0Hz, 1H), 6.78 (d, J=
9.0Hz, 2H), 6.60 (d, J=6.0Hz, 1H), 6.38 (t, J=2.0Hz, 1H), 6.34 (d, J=2.0Hz, 2H), 3.81~
3.75 (m, 1H), 1.76~1.70 (m, 2H), 1.60~1.52 (m, 2H), 1.46~1.39 (m, 2H), 1.32~1.22 (m,
2H).13C NMR(150MHz,CD3OD):δ170.55,160.01 (2×C),158.72,156.40,156.18,151.96,
136.72,131.88,129.11(2×C),123.39,120.44, 116.51,116.23(2×C),112.24,110.02,
109.88(2×C),107.19,106.88,103.18,99.64. 53.05,33.20(2×C),24.91(2×C).(+)-
ESI-MS m/z:468[M+Na]+,484[M+K]+; (-)-ESI-MS m/z:444[M-H]-,480[M+Cl]-;HR-ESI-MS
m/z:446.1598[M+H]+(calcd. for C26H24NO6,446.1598).
Embodiment 31:
N- furfuryl -2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzofuran carboxamides
(31)
Compound 31: faint yellow solid (18.2mg, 29.2%).1H NMR(500MHz,acetone-d6):δ7.43 (d,
J=9.0Hz, 2H), 7.38 (d, J=1.5Hz, 1H), 7.04 (d, J=2.0Hz, 1H), 6.98 (t, J=5.5 Hz, 1H),
6.89 (d, J=2.0Hz, 1H), 6.80 (d, J=9.0Hz, 2H), 6.43 (t, J=2.0Hz, 1H), 6.39 (d, J=2.0Hz,
2H), 6.29 (dd, J=3.0,1.5Hz, 1H), 6.17 (d, J=3.0Hz, 1H), 3.98 (s, 2H)13C NMR(150MHz,
CD3OD):δ170.31,160.13(2×C),158.82,156.39,156.29, 152.48,151.98,143.24,
136.91,131.13,129.06(2×C),123.33,120.69,116.30,116.16 (2×C),112.06,112.29,
109.74(2×C),108.39,103.10,99.95,37.46.(+)-ESI-MS m/z: 457[M]+,480[M+Na]+;(-)-
ESI-MS m/z:456[M-H]-,492[M+Cl]-;HR-ESI-MS m/z: 458.1239[M+H]+(calcd.for
C26H20NO7,458.1234).
Embodiment 32:
N- (phenyl methyl) -2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzofuran formyl
Amine (32)
Compound 32: hazel-color solid (13.7mg, 22.0%).1H NMR(500MHz,acetone):δ7.43 (d,J
=8.5Hz, 1H), 7.26 (t, J=7.5Hz, 2H), 7.20 (d, J=7.5Hz, 2H), 7.19 (t, J=7.5Hz, 1H), 7.05
(d, J=2.0Hz, 1H), 7.02 (t, J=5.5Hz, 1H), 6.92 (d, J=2.0Hz, 1H), 6.80 (d, J=8.5Hz, 2H),
6.45 (d, J=2.0Hz, 1H), 6.41 (d, J=2.0Hz, 1H), 4.03 (d, J=6.0Hz, 2H)13C NMR(125MHz,
CD3OD):δ170.57,169.01,158.70(2×C),157.35,154.96, 154.83,150.55,137.90,
135.47,129.93,127.99(2×C),127.62(2×C),127.37(2×C), 126.65,121.88,119.19,
114.89,114.69(2×C),110.68,108.53(2×C),101.71,98.44, 43.10.(+)-ESI-MS m/z:
468.0[M+H]+,490.0[M+Na]+,505.9[M+K]+.HR-ESI-MS m/z:468.1449[M+H]+(calcd.for
C28H22NO6,468.1442).
Embodiment 33:
N- methyl-N- (phenyl methyl) -2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzo furan
It mutters formamide (33)
Compound 33: faint yellow solid (51.0mg, 81.3%, for a pair of of enantiomter)1H NMR(500 MHz,
Acetone): δ 7.46 (d, J=8.5Hz, 2H), 7.45 (d, J=9.0Hz, 2H), 7.19-7.32 (m, 8H), 7.07-7.10
(m, 2H), 7.02 (d, J=2.1Hz, 1H), 6.99 (d, J=2.1Hz, 1H), 6.81 (d, J=8.9Hz, 4H), 6.79 (d, J
=2.1Hz, 1H), 6.72 (d, J=2.1Hz, 1H), 6.45 (t, J=2.2Hz, 1H), 6.43 (d, J=2.2Hz, 1H),
6.40-6.42 (m, 3H), 5.10 (d, J=14.7Hz, 1H), 4.47 (d, J=15.8Hz, 1H), 3.70 (d, J=15.9Hz,
1H), 3.22 (d, J=14.8Hz, 1H), 2.48 (s, 3H), 2.45 (s, 3H)13C NMR(125MHz,acetone):δ
170.57,170.47,158.87,158.80,157.76(2×C),157.73(2 ×C),155.70,155.62,155.03,
154.85,150.97,150.90,136.66,136.32,134.52,134.49, 129.10,128.74,128.59(2×C),
128.52(2×C),127.90(2×C),127.86(2×C),127.81 (2×C),127.58,127.30,127.07(2×
C),121.88,121.85,118.85,118.51,115.03(2×C), 115.01(2×C),114.93,114.87,
110.43,109.87,108.49(4×C),102.18,102.12,98.31, 98.17,54.94,49.90,35.49,
31.34.(+)-ESI-MS m/z:504[M+Na]+;(-)-ESI-MS m/z:480 [M-H]-,515.9[M+Cl]-;HR-ESI-
MS m/z:482.1590[M+H]+(calcd.for C29H24NO6, 482.1598).
Embodiment 34:
N- (4- aminomethyl phenyl) -2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzofuran first
Amide (34)
Compound 34: hazel-color solid (21.2mg, 34.0%).1H NMR(500MHz,CD3OD): δ 7.40 (d, J=
9.0Hz, 2H), 7.16 (d, J=8.5Hz, 2H), 7.04 (d, J=2.0Hz, 1H), 6.99 (d, J=8.5 Hz, 2H), 6.89
(d, J=2.0Hz, 1H), 6.69 (d, J=9.0Hz, 2H), 6.29 (d, J=2.0Hz, 1H), 5.93 (s, 1H), 2.27 (s,
3H);13C NMR(125MHz,CD3OD):δ168.64,159.95,158.78, 156.47,156.34,152.02,136.53,
136.50,134.77,131.91,129.57,129.05,123.37,121.61, 120.90,116.53,116.13,
112.25,109.48,102.92,100.08,21.00.(+)-ESI-MS m/z:468 [M+H]+,490[M+Na]+;(-)-
ESI-MS m/z:466[M-H]-,502[M+Cl]-;HR-ESI-MS m/z: 468.1448[M+H]+(calcd.for
C28H22NO6,468.1442).
Embodiment 35:
N- (4- chlorphenyl) -2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4- benzofuran formyl
Amine (35)
Compound 35: hazel-color solid (46.6mg, 74.2%).1H NMR(500MHz,CD3OD) 7.41 (d, J=of δ
7.5Hz, 1H), 7.32 (d, J=8.0Hz, 1H), 7.16 (d, J=7.5Hz, 1H), 7.06 (s, 1H), 6.90 (s, 1H), 6.70
(d, J=8.0Hz, 1H), 6.28 (s, 1H), 5.88 (d, J=2.0Hz, 1H);13C NMR(126 MHz,CD3OD):δ168.77,
160.01(2×C),158.85,156.46,156.43,152.07,138.00, 136.62,131.58,129.83,129.05
(2×C),128.99(2×C),123.28,122.48(2×C),120.97, 116.40,116.16(2×C),112.23,
109.36(2×C),102.76,100.29.(+)-ESI-MS m/z:488.0 [M+H]+,510[M+Na]+;525.9[M+K]+;
(-)-ESI-MS m/z:485.9[M-H]-,521.9[M+Cl]-; HR-ESI-MS m/z:488.0907[M+H]+
(calcd.for C27H19ClNO6,488.0895).
Embodiment 36:
Compound 36
N- [2- (1H- indol-3-yl) ethyl)] -2- (4- hydroxy phenyl) -3- (3,5- dihydroxy phenyl) -6- hydroxyl -4-
Benzofuran carboxamides (36)
Compound 36: hazel-color solid (33.9mg, 53.6%).1H NMR(500MHz,acetone-d6):δ7.60 (d,
J=7.5Hz, 1H), 7.41 (d, J=9.0Hz, 2H), 7.34 (d, J=7.5Hz, 1H), 7.11 (s, 1H), 7.06 (dt, J=
1.0,7.5Hz, 1H), 7.02 (d, J=2.0Hz, 1H), 7.01 (dt, J=1.0,7.5Hz, 1H), 6.93 (d, J=2.0Hz,
1H), 6.80 (d, J=9.0Hz, 2H), 6.43-6.38 (m, 3H), 3.20 (t, J=8.0Hz, 2H), 2.75 (t, J=8.0Hz,
2H).13C NMR(125MHz,CD3OD):δ170.55,160.14(2×C), 158.81,156.45,156.28,152.02,
138.08,136.92,131.59,129.13(2×C),128.73,123.36, 123.18,122.23,120.54,119.52
(2×C),116.38,116.15(2×C),113.42,112.28,112.07, 109.79,103.20,99.86,41.99,
25.76.(+)-ESI-MS m/z:521[M+H]+,543[M+Na]+; (-)-ESI-MS m/z:519[M-H]-,554.9[M+
Cl]-;HR-ESI-MS m/z:521.1721[M+H]+(calcd. for C31H25N2O6,521.1707).
Following (the pharmacological evaluation part of anti-inflammatory and immunosuppressive activity the pharmacological test procedures and result of the compounds of this invention
Compound numbers correspond to embodiment in compound numbers):
Embodiment 1: the inhibitory activity that compound generates LPS induction Primary mouse peritoneal macrophage NO.
Macrophage executes body non-specific immune function, can produce the inflammation such as NO under bacteria lipopolysaccharide LPS induction
Sex factor participates in simultaneously inducing inflammatory reaction, has higher water during inflammation immunologic process initial stage and pathological development
It is flat.By detecting the mouse macrophage NO production quantity of originally culture, can be used as external preliminary observation and screening have it is certain anti-inflammatory
The index of active component or compound.
Experimental method:
It takes Primary mouse peritoneal macrophage to be inoculated in 96 orifice plates, different untested compounds (10 is added-5M) and positive
Comparison medicine dexamethasone (Dex) protects 1h in advance;Then, 1 μ g/ml LPS is added in 37 DEG C, 5%CO2It is cultivated for 24 hours in incubator
Afterwards, supernatant is collected, using the content of Griess method measurement NO Meanwhile cell proliferation inhibition rate is measured with mtt assay, and measure
The IC with remarkable inhibiting activity compound is generated to NO50(being calculated with Probit weighted regression analysis method).
Experimental result:
The results are shown in Table 1, and compared with lead compound Amurensin H, the compound through structure of modification is being kept
While active, toxicity is significantly reduced.Wherein, compound 11,18,30,33,35,36, not only there is significant NO to generate and inhibit
Activity, and toxicity is substantially less than Amurensin H and positive control drug.
The influence that table 1.Amurensin H derivative generates LPS induction Primary mouse peritoneal macrophage NO
*Compound numbers correspond to the compound numbers in embodiment
Embodiment 2: influence of the compound to croton oil inducing mouse otitis
Experimental method:
The male mice in kunming of 18-20g is taken, random to be grouped, groups of animals applies croton oil respectively at left ear two sides
0.02ml;After 30 minutes, groups of animals gives test-compound respectively with the subcutaneous injection of 50mg/kg weight, and model control group is given
Give isometric solvent;After 4h is administered, takes off neck and put to death mouse, cut ears along auricle base line, diameter 6mm punch removes a left side respectively
The auricle of auris dextra same position, assay balance weighing, calculates ear swelling (ear swelling=left auricle weight-auris dextra sheet weight)
With ear swelling inhibiting rate
Experimental result:
Experimental result is as shown in table 2, and compared with model control group, compound 18 can significantly mitigate the mouse of croton oil induction
Otitis (P < 0.01 or 0.05).
Influence (Mean ± SD, n=10) of the table 2.Amurensin H derivative to croton oil inducing mouse otitisa.
aCompared with model group, " * " indicates p < 0.05, and " * * " indicates p < 0.01.
bCompound numbers correspond to the compound numbers in embodiment
Embodiment 3: the influence of compound Carrageenan inducing mouse foot swelling
Experimental method:
The male mice in kunming of 18-20g is taken, random to be grouped, groups of animals is subcutaneously injected 0.1% jiao respectively at left foot bottom
Pitch dish glue 0.05ml;After 30 minutes, groups of animals gives test-compound, model pair respectively with the subcutaneous injection of 50mg/kg weight
Isometric solvent is given according to group;It after 4h is administered, takes off neck and puts to death mouse, cut biped along ankle-joint, assay balance weighing calculates foot
Swelling (degree of paw swelling=left foot weight-right lumping weight amount) and foot swelling inhibiting rate
Experimental result:
Experimental result is as shown in table 3, and compared with model control group, compound 18 can significantly mitigate the small of carrageenan induction
Mouse foot swelling (P < 0.01).
Table 3.Amurensin H derivative Carrageenan inducing mouse foot swelling influence (Mean ± SD, n=
10)a.
aCompared with model group, " * " indicates p < 0.05, and " * * " indicates p < 0.01.
bCompound numbers correspond to the compound numbers in embodiment.
Claims (21)
1. as (2,3- diphenyl -4- replaces plain (Amurensin H) derivative of 7,8- dehydrogenation grapevine penta shown in logical formula (I)
Benzofuran derivatives) and its pharmaceutically acceptable salt:
Wherein, X is selected from O, NR6,S;
R1Selected from H, substituted or unsubstituted C3-8Naphthenic base, substituted or unsubstituted phenyl, substituted or unsubstituted indyl,
Substituted or unsubstituted furyl, substituted or unsubstituted naphthalene, substituted or unsubstituted quinolyl, substituted or unsubstituted pyrrole
Piperidinyl;Wherein the substituent group of the naphthenic base, phenyl, indyl, furyl, naphthalene, quinolyl and pyridyl group is selected from hydroxyl, nitre
Base, cyano, amino, methylamino, dimethylamino, C1-6Alkyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6
Alkylthio group, methylene-dioxy, carboxyl, F, Cl, Br, I, Glu, SO3H、PO3H2;Replace type include it is monosubstituted, two replace or
Three replace;
L1Selected from substituted or unsubstituted C0-16Linear or branched alkyl group, substituted or unsubstituted C0-16Linear chain or branched chain acyl
Base, substituted or unsubstituted C2-16Linear chain or branched chain alkenyl, C2-6Alkynyl;The substituent group be selected from hydroxyl, nitro, cyano,
Amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6Alkylthio group, F, Cl,
Br,I;
R6Independently selected from H, substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C1-6Acyl group;Wherein, substituent group
Selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkoxy, phenyl, F, Cl, Br, I;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
2. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 1 and its pharmaceutically acceptable salt, which is characterized in that
Shown in the compound such as general formula (IA):
Wherein, R1Selected from H, substituted or unsubstituted C3-8Naphthenic base, substituted or unsubstituted phenyl, substituted or unsubstituted Yin
Diindyl base, substituted or unsubstituted furyl, substituted or unsubstituted naphthalene, substituted or unsubstituted quinolyl, substitution do not take
The pyridyl group in generation;The naphthenic base, phenyl, indyl, furyl, naphthalene, quinolyl and pyridyl group substituent group be selected from hydroxyl,
Nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy,
C1-6Alkylthio group, methylene-dioxy, carboxyl, F, Cl, Br, I, Glu, SO3H、PO3H2;Replacing type includes monosubstituted, two substitutions
Or three replace;
L1Selected from substituted or unsubstituted C0-16Linear or branched alkyl group, substituted or unsubstituted C0-16Linear chain or branched chain acyl
Base, substituted or unsubstituted C2-16Linear chain or branched chain alkenyl, C2-6Alkynyl;The substituent group be selected from hydroxyl, nitro, cyano,
Amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6Alkylthio group, F, Cl,
Br,I;
R6Independently selected from H, substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C1-6Acyl group;Wherein, substituent group
Selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkoxy, phenyl, F, Cl, Br, I;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
3. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 2 and its pharmaceutically acceptable salt, which is characterized in that
The compound such as general formula (IAa), (IAb), shown in (IAc):
Wherein, L1Selected from substituted or unsubstituted C0-16Linear or branched alkyl group, substituted or unsubstituted C0-16Straight chain or branch
Chain acyl, substituted or unsubstituted C2-16Linear chain or branched chain alkenyl;The substituent group be selected from hydroxyl, nitro, cyano, amino,
Methylamino, dimethylamino, phenyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, F, Cl, Br, I;
R6Independently selected from H, substituted or unsubstituted C1-6Alkyl, substituted or unsubstituted C1-6Acyl group;Wherein, substituent group
Selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkoxy, phenyl, F, Cl, Br, I;
R7、R8、R9It is each independently selected from hydrogen, hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkyl, C1-6
Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6Alkylthio group, methylene-dioxy, F, Cl, Br, I, Glu, SO3H、
PO3H2;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
4. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 3 and its pharmaceutically acceptable salt, it is characterised in that:
The L1Selected from C0、C1、C2、C3Straight chained alkyl;
R6Independently selected from H, C1、C2、C3Straight chained alkyl;
R7、R8、R9It is each independently selected from hydrogen, hydroxyl, methoxyl group, acetyl group, Cl;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl.
5. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 2 and its pharmaceutically acceptable salt, which is characterized in that
Shown in the compound such as general formula (IAd):
Wherein, R10Independently selected from hydrogen, substituted or unsubstituted C3-8Naphthenic base, substituted or unsubstituted C1-16Straight chain or
Branched alkyl, substituted or unsubstituted C1-16Linear chain or branched chain acyl group, substituted or unsubstituted C2-16Linear chain or branched chain alkene
Base, C2-6Alkynyl;Wherein, the substituent group is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, phenyl, C1-6
Alkoxy, C1-6Acyloxy, C1-6Alkylthio group, F, Cl, Br, I;
R6Independently selected from H, substituted or unsubstituted C1-6Alkyl;Wherein, substituent group be selected from hydroxyl, nitro, cyano, amino,
Methylamino, dimethylamino, C1-6Alkoxy, phenyl, F, Cl, Br, I;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
6. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 5 and its pharmaceutically acceptable salt, it is characterised in that:
The R10Selected from substituted or unsubstituted C1-16Linear or branched alkyl group, substituted or unsubstituted C3-8Naphthenic base;
Wherein, the substituent group is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy, C1-6's
Acyl group, C1-6Acyloxy, C1-6Alkylthio group, F, Cl, Br, I;
R6Independently selected from H, C1、C2、C3Straight chained alkyl;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl, acetyl group.
7. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 6 and its pharmaceutically acceptable salt, it is characterised in that:
The R10Selected from substituted or unsubstituted C3-12Linear or branched alkyl group, substituted or unsubstituted C5-6Naphthenic base;
Wherein, the substituent group is selected from hydrogen, hydroxyl, methylamino, dimethylamino, methoxyl group, acetyl group, Cl;
R6Independently selected from H, C1、C2、C3Straight chained alkyl;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl, acetyl group.
8. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 1 and its pharmaceutically acceptable salt, which is characterized in that
Shown in the compound such as general formula (IB):
Wherein, R1Selected from H, substituted or unsubstituted C3-8Naphthenic base, substituted or unsubstituted phenyl, substituted or unsubstituted Yin
Diindyl base, substituted or unsubstituted furyl, substituted or unsubstituted naphthalene, substituted or unsubstituted quinolyl, substitution do not take
The pyridyl group in generation;The naphthenic base, phenyl, indyl, furyl, naphthalene, quinolyl and pyridyl group substituent group be selected from hydroxyl,
Nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy,
C1-6Alkylthio group, methylene-dioxy, carboxyl, F, Cl, Br, I, Glu, SO3H、PO3H2;Replacing type includes monosubstituted, two substitutions
Or three replace;
L1Selected from substituted or unsubstituted C0-16Linear or branched alkyl group, substituted or unsubstituted C0-16Linear chain or branched chain acyl
Base, substituted or unsubstituted C2-16Linear chain or branched chain alkenyl, C2-6Alkynyl;The substituent group be selected from hydroxyl, nitro, cyano,
Amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6Alkylthio group, F, Cl,
Br,I;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
9. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 8 and its pharmaceutically acceptable salt, it is characterised in that
The compound such as general formula (IBa), (IBb), shown in (IBc):
L1Selected from substituted or unsubstituted C0-16Linear or branched alkyl group, substituted or unsubstituted C0-16Linear chain or branched chain acyl
Base, substituted or unsubstituted C2-16Linear chain or branched chain alkenyl;The substituent group is selected from hydroxyl, nitro, cyano, amino, first ammonia
Base, dimethylamino, C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, F, Cl, Br, I;
R11、R12、R13It is each independently selected from hydrogen, hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, C1-6Alkyl,
C1-6Alkoxy, C1-6Acyl group, C1-6Acyloxy, C1-6Alkylthio group, methylene-dioxy, F, Cl, Br, I, Glu, SO3H、
PO3H2;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
10. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 9 and its pharmaceutically acceptable salt, feature exist
In,
The L1Selected from C0、C1、C2、C3Straight chained alkyl;
R11、R12、R13It is each independently selected from hydrogen, hydroxyl, methoxyl group, acetyl group, Cl;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl, acetyl group.
11. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 8 and its pharmaceutically acceptable salt, feature exist
In shown in the compound such as general formula (IBd):
Wherein, R14Independently selected from hydrogen, substituted or unsubstituted C3-8Naphthenic base, substituted or unsubstituted C1-16Straight chain or
Branched alkyl, substituted or unsubstituted C1-16Linear chain or branched chain acyl group, substituted or unsubstituted C2-16Linear chain or branched chain alkene
Base, C2-6Alkynyl;The substituent group is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, phenyl, C1-6Alcoxyl
Base, C1-6Acyl group, C1-6Acyloxy, F, Cl, Br, I;
R2、R3、R4、R5It is each independently selected from hydrogen, C1-6Alkyl, C1-6Acyl group, Glu, SO3H、PO3H2;
Glu indicates β-D glucopyranosyl;SO3H indicates sulfonyl;PO3H2Indicate phosphoryl.
12. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 11 and its pharmaceutically acceptable salt, feature exist
In:
The R14Selected from substituted or unsubstituted C1-16Linear or branched alkyl group, substituted or unsubstituted C3-8Naphthenic base;
Wherein, the substituent group is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy, replace
Base is selected from hydroxyl, nitro, cyano, amino, methylamino, dimethylamino, phenyl, C1-6Alkoxy, C1-6Acyl group, C1-6Acyl
Oxygroup, F, Cl, Br, I;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl, acetyl group.
13. the plain derivative of 7,8- dehydrogenation grapevine penta according to claim 12 and its pharmaceutically acceptable salt, feature exist
In:
The R14Selected from substituted or unsubstituted C3-12Linear or branched alkyl group, substituted or unsubstituted C5-6Naphthenic base;
The substituent group is selected from hydrogen, methylamino, dimethylamino, methoxyl group, acetyl group, Cl;
R2、R3、R4、R5It is each independently selected from hydrogen, methyl, acetyl group.
14. the plain derivative of any one of -13 7,8- dehydrogenation grapevine penta and its pharmaceutically acceptable according to claim 1
Salt, which is characterized in that the compound is selected from following group:
15. a kind of pharmaceutical composition, by described in any item 7,8- dehydrogenation grapevine, penta elements of the claim 1-14 of effective dose
Derivative and its pharmaceutically acceptable salt and pharmaceutically acceptable carrier or auxiliary material composition.
16. pharmaceutical composition according to claim 15, which is characterized in that the pharmaceutical composition is selected from tablet, capsule, ball
Agent, injection.
17. pharmaceutical composition according to claim 15, which is characterized in that described pharmaceutical composition is selected from sustained release preparation, controlled release
Preparation and various particulate delivery systems.
18. the claim 1-14 plain derivative of described in any item 7,8- dehydrogenation grapevines penta and its pharmaceutically acceptable salt exist
Application in preparation treatment and/or prevention of inflammation and/or immunosuppressive drug.
19. the claim 1-14 plain derivative of described in any item 7,8- dehydrogenation grapevines penta and its pharmaceutically acceptable salt exist
Application in preparation treatment and/or prevention of inflammation and/or immunosupress related disease product.
20. application according to claim 19, wherein inflammation and immunosupress related disease include: rheumatoid arthritis, bone
Arthritis, rheumatic arthritis, urarthritis, lupus erythematosus syndrome, bronchitis, bursal synovitis, tenosynovitis, ox-hide
It is tinea, eczema, burn, dermatitis, inflammatory bowel disease, Ke Laoen disease, gastritis, irritable bowel syndrome, ulcerative colitis, multiple hard
Change that disease, Autoimmune Encephalomyelitis, colorectal cancer, arteritis nodosa, thyroiditis, wind-heat be wet, gingivitis, periodontal
Swelling, myocardial ischemia, various infectious pneumonias, physics and chemistry pneumonia and the metamorphosis occurred after inflammation, canker sore, ephritis, damage
Reactive pneumonia, Chronic Obstructive Pulmonary Disease, asthma, proctalgia fugax and rectum split, liver and gallbladder capsulitis, cholangitis, hardenability
Cholangitis, primary biliary cirrhosis and cholecystitis.
21. application according to claim 19, which is characterized in that the product is selected from drug, health care product.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711021002 | 2017-10-27 | ||
CN2017110210029 | 2017-10-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109721579A true CN109721579A (en) | 2019-05-07 |
CN109721579B CN109721579B (en) | 2022-11-04 |
Family
ID=66295442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811265797.2A Active CN109721579B (en) | 2017-10-27 | 2018-10-29 | 7, 8-dehydrograpevine derivatives, preparation method, pharmaceutical composition and use thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109721579B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112791080A (en) * | 2021-01-21 | 2021-05-14 | 中国药科大学 | Application of resveratrol dimer TVN in preparation of medicine for treating osteoarthritis |
CN113304139A (en) * | 2021-06-30 | 2021-08-27 | 贵州医科大学 | Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs |
CN114075102A (en) * | 2020-08-19 | 2022-02-22 | 中国医学科学院药物研究所 | 2, 3-diaryl indene derivative, preparation method, pharmaceutical composition and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1154697A (en) * | 1995-05-19 | 1997-07-16 | 协和发酵工业株式会社 | Oxygen-contg. heterocyclic compound |
WO1999006388A2 (en) * | 1997-07-31 | 1999-02-11 | Proteome Sciences Plc. | Pharmaceutical compounds isolated from aristolochia taliscana |
US20100292190A1 (en) * | 2005-02-14 | 2010-11-18 | Bionomics Limited | Novel tubulin polymerisation inhibitors |
-
2018
- 2018-10-29 CN CN201811265797.2A patent/CN109721579B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1154697A (en) * | 1995-05-19 | 1997-07-16 | 协和发酵工业株式会社 | Oxygen-contg. heterocyclic compound |
WO1999006388A2 (en) * | 1997-07-31 | 1999-02-11 | Proteome Sciences Plc. | Pharmaceutical compounds isolated from aristolochia taliscana |
US20100292190A1 (en) * | 2005-02-14 | 2010-11-18 | Bionomics Limited | Novel tubulin polymerisation inhibitors |
Non-Patent Citations (2)
Title |
---|
DILEEP KUMAR SINGH ET AL1.: "Skeletal Reorganization: Synthesis of Diptoindonesin G from Pauciflorol F", 《J. ORG. CHEM.》 * |
KYUNGSUN KIM ET AL.: "Total Synthesis of Diptoindonesin G via a Highly Eficient Domino Cyclodehydration/Intramolecular Friedel-Crafts Acylation/Regioselective Demethylation Sequence", 《ORG. LETT.》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114075102A (en) * | 2020-08-19 | 2022-02-22 | 中国医学科学院药物研究所 | 2, 3-diaryl indene derivative, preparation method, pharmaceutical composition and application thereof |
CN114075102B (en) * | 2020-08-19 | 2024-01-12 | 中国医学科学院药物研究所 | 2, 3-diaryl indene derivative, preparation method, pharmaceutical composition and application thereof |
CN112791080A (en) * | 2021-01-21 | 2021-05-14 | 中国药科大学 | Application of resveratrol dimer TVN in preparation of medicine for treating osteoarthritis |
CN113304139A (en) * | 2021-06-30 | 2021-08-27 | 贵州医科大学 | Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs |
CN113304139B (en) * | 2021-06-30 | 2022-04-29 | 贵州医科大学 | Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs |
Also Published As
Publication number | Publication date |
---|---|
CN109721579B (en) | 2022-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109721580A (en) | The plain derivative of 3- phenyl -7,8- dehydrogenation grapevine penta, its preparation method and pharmaceutical composition and purposes | |
CN109721579A (en) | The plain derivative of 7,8- dehydrogenation grapevine penta, its preparation method and pharmaceutical composition and purposes | |
CN107163011B (en) | 3- (3,4,5- trimethoxybenzoyl)-benzofurans Antitubulin and its preparation method and application | |
CN102344481A (en) | Derivatives of 3-O-caffeoyloleanane type pentacyclic triterpene, preparation method thereof and application thereof | |
CN101296694A (en) | Pharmaceutical gallium compositions and methods | |
US20210380514A1 (en) | Solid compositions of cocrystals of cannabinoids | |
CN113735709B (en) | Cannabidiol-2-butyrate and application thereof | |
CN113666824B (en) | Cannabidiol-2-propionate and application thereof | |
CN109897021A (en) | The plain derivative of grapevine penta, its preparation method and pharmaceutical composition and purposes | |
CN108884124A (en) | Caborane compounds and its application method | |
CN104086617B (en) | Close dimethylamine derivative, the preparation method and its usage of flowers and trees ketone Cleistanone | |
CN101896477A (en) | The five crystal forms of the nicousamide, the preparation methods, the pharmaceutical compositions and the uses thereof | |
CN109970679A (en) | Paeonol thiazole and its preparation method and application | |
CN103145636B (en) | 1,4-diacyl-3,6-diphenyl-1,4-dihydrotetrazine compound as well as preparation method and application thereof | |
CN110922415B (en) | Synthesis and application of novel anti-tumor active compound | |
CN101602786B (en) | N<6>-substituted adenosine derivative, preparation method thereof, drug composition and application | |
CN101974016A (en) | Amide compound and preparation method and applications thereof | |
CN104045615A (en) | (1S)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-D-glucose of crystal form A, and preparation method and application thereof | |
CN108864082A (en) | One kind has the indolizine class compound and its derivative of anticancer activity | |
CN103304556B (en) | Schiff bases compounds containing chromene, Preparation Method And The Use | |
WO2000044757A1 (en) | Hesperitin pro-forms with enhanced bioavailability | |
CN115246802B (en) | Grape extract derivative, its preparation method, pharmaceutical composition and use | |
CN106220582A (en) | N, 4 diaryl thiazole 2 aminated compoundss and the purposes as tumor cell proliferation inhibitor thereof | |
CN102786458A (en) | Pyrrole formamide derivative, and preparation method and application thereof | |
CN101786952B (en) | Anthraquinone compound and preparation method and medical application of lysine salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |